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S.M. TOUHIDUL ISLAM. Nonalcoholic Steatohepatitis: Role of Gut Microbiota is 
Dependent on Lipopolysaccharide-Toll like Receptor-4 Axis. (Under the direction of 
KENNETH D. CHAVIN) 
Abstract 
Hepatic steatosis is the hepatic manifestation of metabolic syndrome which is 
increasingly becoming a health problem worldwide, especially in the western hemisphere. 
Hepatic steatosis is benign, but long standing hepatic steatosis can lead to non-alcoholic 
steatohepatitis (NASH).  NASH is a form of nonalcoholic fatty liver disease where 
excessive fat accumulation in the liver leads to chronic inflammation of a patient without 
any history of alcohol abuse.  However, the mechanism underlying the progression of 
hepatic steatosis to NASH is unclear.  Role of gut microbiota in metabolic syndrome has 
long been reported.  Here, we hypothesized that gut microbiota plays an important role in 
the modulation of NASH through the involvement of lipopolysaccharide (LPS)-toll-like 
receptor-4 (TLR-4) pathway in dietary fat mediated hepatic steatosis.  To test this 
hypothesis, germ free or broad-spectrum antibiotics-treated mice were fed high fat diet, 
which resulted in decreased level of inflammation in their fatty liver compared to the 
specific pathogen free control mice.  This result demonstrated the involvement of gut 
microbiota in mediating NASH.  To address the role of LPS-TLR-4 pathway, broad 
spectrum antibiotics-treated mice fed high fat diet were injected i.p. with low dose LPS, 
resulting in an increased level of inflammation in the liver which was decreased upon the 
co-treatment with TAK-242, an inhibitor of TLR-4.  To investigate the role of TLR-4-
expressing kupffer cells in mediating NASH, wild-type kupffer cells in the liver of wild-type 
mice were replaced with TLR-4 KO kupffer cells by bone marrow transplantation, which 
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resulted in a decreased level of inflammation in liver upon NASH induction.  It was also 
investigated whether the peroxisomal anti-oxidative function is altered in the livers of mice 
fed high fat diet in a TLR-4 dependent manner.   Indeed, the level and function of catalase, 
the principal antioxidative enzyme in peroxisomes, was decreased in mice fed high fat 
diet, which was reversed in TLR-4 KO mice fed high fat diet.  This individual piece of data 
demonstrated the role of TLR-4 pathway in modulating NASH through the alteration of 
peroxisomal anti-oxidative function.  In conclusion, this project established the role of gut 





















Table of contents 
Chapter Heading Page 
Acknowledgements iii 
Abstracts v 
List of abbreviations xii 
List of figures xiv 
List of tables xvi 
   
Chapter 1  1 
An Overview of Nonalcoholic Steatohepatitis and Gut Microbiota 1 
 Epidemiology of NAFLD and NASH 2 
 Risk of progression of NASH to end stage liver diseases 2 
 From metabolic syndrome to NASH 3 
 A ‘Two-hit hypothesis’ to explain the pathogenesis of NASH 7 
 Pro-inflammatory mediators of NASH 7 
 Gut microbiota and their contribution to human health 9 
 Dynamic composition of gut microbiota and metabolic syndrome 10 
 Gut microbiota bridges gut-liver axis 11 
 Gut microbiota induces pro-inflammatory pathways through the 
interaction with toll-like receptors  
12 
 Potential role of low grade chronic endotoxemia in metabolic 
syndrome 
13 
 TLR-4 pathway is essential in the modulation of metabolic 
syndrome 
17 
 Potential role of LPS-TLR-4 axis in NASH 17 
   
Chapter 2  18 
Materials and Methods 18 
 Animal experiment 19 
 Partial hepatectomy 20 
 Treatment with broad-spectrum antibiotic, LPS and TLR-4 
inhibitor 
21 
 Bone marrow transplantation and depletion of kupffer cells  23 
 ALT and AST assays 25 
 Endotoxin assays  25 
 Liver histology and immunohistochemical staining 26 
 Quantitative real time reverse transcriptase polymerase chain 
reaction (RT-PCR)  
28 
 Western blot analysis 29 
 Catalase activity assay  31 
 16S rRNA analyses 31 
 Isolation of kupffer cells and flow cytometric analyses 32 
 Statistical analyses 33 
   
Chapter 3  34 
ix 
 
Dietary Model of NASH: Pathology of NASH Develops at a Higher Level 





 Both LD and MD led to the development of hepatic steatosis at 
week 16 and 32, while MD showed a non-significant higher trend 
than LD  
39 
 Both LD and MD led to the development of chronic inflammation 
in the fatty liver, while MD displayed a non-significant higher 
trend than LD at week 16 and 32 
39 
 Mice fed LD or MD both showed an indication of fibrosis in the 
fatty liver, yet feeding with MD showed a higher level of 
expression of TGF-β than feeding with LD 
43 
Discussion  45 
   
Chapter 4  48 
High Fat Diet-mediated Nonalcoholic Steatohepatitis Impairs Hepatic 





 Mice fed LD and MD led to the development of NASH in both 
resected and regenerated livers 
51 
 Both LD or MD caused damage in resected and regenerated 
livers 
51 
 NASH-affected livers of mice fed MD or LD demonstrated 
impaired regeneration following partial hepatectomy (PHx) 
54 
Discussion   57 
   
Chapter 5  59 




 GF mice developed less steatosis in their livers compared to the 
SPF mice 
63 
 Steatotic livers in GF mice were resistant to NASH 63 
 GF mice fed MD had decreased level of collagen accumulation 
in their livers compared to the SPF mice fed MD 
68 
 Broad spectrum antibiotics-treated mice fed MD showed similar 
levels of steatosis, but had a decreased level of NASH compared 
to the control mice fed MD 
70 
 Conventionalization of GF mice fed MD resulted in increased 




 Composition of gut microbial community was altered in mice fed 
MD 
80 
Discussion  83 
   
Chapter 6  86 
Role of Gut Microbiota in Causing NASH is Dependent on LPS-TLR-4-





 Diminishing of gut microbiota resulted in reduced concentration 
of serum endotoxin which was restored upon LPS injection 
89 
 LPS injection resulted in increased level of NASH in broad 
spectrum antibiotics-treated mice fed MD 
89 
 Administration of TLR-4 inhibitor (TAK-242) blunted the effect of 
injection of low dose LPS resulting in decreased level of NASH 
91 
 TLR-4 has an obvious role in the modulation of NASH in mice 
fed MD 
96 
 TLR-4-expressing kupffer cells play a crucial role in mediating 
NASH in mice fed MD 
100 
 Reconstituted kupffer cells were derived from the transplanted 
bone marrow 
107 
Discussion  109 
   
Chapter 7  111 
Peroxisomal Structural and Anti-oxidative Function is Compromised in 





 Peroxisomal structure is altered in the livers of mice fed MD in a 
TLR-4 dependent manner 
116 
 Catalase level and function are altered in the livers of mice fed 
MD in a TLR-4 dependent manner 
116 
Discussion  121 
   
Chapter 8  124 
Conclusions and Overall Discussion 124 
 Study of NASH in mice fed high fat diet represents a clinically 
relevant model 
125 
 Gut microbiota spans gut-liver axis in causing NASH 127 
 Gut microbial community is altered in NASH 128 
 Altered gut permeability facilitates the elevation of circulating 
endotoxin level 
129 
 LPS-TLR-4 pathway plays an essential role in mediating NASH 130 
xi 
 
TLR-4 pathway is a promising target for therapeutic intervention 
against NASH and ischemia/reperfusion injury in liver 
transplantation 
 Therapeutic interference of LPS-TLR-4 pathway may improve 
hepatic regeneration following partial hepatectomy in steatotic 
liver 
131 
 Why peroxisomes are important in controlling oxidative stress 133 
 Peroxisomal anti-oxidative function is impaired in NASH 134 
 Intervention of TLR-4 pathway can improve peroxisomal anti-
oxidative function 
135 

























List of abbreviations 
ATM Adipose Tissue Macrophage 
AFLD Fatty Liver Disease 
ALD Alcoholic Steatohepatitis 
ALT Alanine Transaminase 
AST Aspartate  Transaminase 
α-SMA α-Smooth Muscle Actin 
BrdU 5-romo-2'-deoxyuridine 
ChREBP Carbohydrate Response Element Binding Protein  
CCL-2 C-C Motif Chemokine Ligand-2 
CD Control Diet 
Col-1a Collagen-1a 
DAPI 4′,6-diamidino-2-phenylindole 
∆∆Ct Delta Delta Threshold Cycles 
ER Endoplasmic Reticulum 
ECM  Extracellular Matrices 
Fc Fragment Crystallizable  
FFA Free Fatty Acid 
FFPE Formalin Fixed Paraffin Embedded 
FOXO1 Forkhead Box Protein O1 
GF  Germ Free 
GMR Gut Microbiota Re-constituted 
Gy Gray 
HCV Hepatitis C Virus 
HBV Hepatitis B Virus 
HIV human immunodeficiency virus 
H2O2 Hydrogen Peroxide 
HPRT Hypoxanthine-guanine Phosphoribosyl Transferase 
HSCs Hepatic Stellate Cells 




LAL Limulus Amebocyte Lysate  
LD Lard-based Unsaturated High Fat Diet 
LRR Leucine Rich Repeats 
MAMPs Microbe Associated Molecular Patterns 
MAPK Mitogen-Activated Protein Kinase 
MD Milk-based Saturated High Fat Diet 
xiii 
 
mTORC2 mTOR Complex 2 
NAFLD Nonalcoholic Fatty Liver Disease 
NASH Nonalcoholic Steatohepatitis 
NFκB Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells  
OCT Optimum Cutting Temperature 
PDGF Platelet Derived Growth Factor 
PDK1 3-Phosphiinositide–Dependent Kinase-1 
PHx Partial Hepatectomy 
P13K Phosphoinositide 3-Kinase   
PMP70 Peroxisomal Membrane Protein 70 
PNPLA3 Patatin-like Phospholipase Domain-containing 3 
PPAR-α Peroxisome Proliferator-activated Receptor-α 
PPAR-α Peroxisome Proliferator-activated Receptor-γ 
PTEN Phosphatase and Tensin Homologue 
RIPA Radioimmunoprecipitation Assay Buffer 
ROS Reactive Oxygen Species 
SLE Systemic Lupus Erythematosus 
SNP Single Nucleotide Polymorphism 
SPF Specific Pathogen Free 
SREBP-1c Sterol Regulatory Element Binding Protein-1c 
STAT3 Signal Transducer and Activator of Transcription 3  
T2DM Type-2 Diabetes Mellitus 
TCA Tri-Carboxylic Acid 
TG Triglyceride 
TGF-β Transforming Growth Factor-beta 
TIR Toll/Interleukin-1 Receptor 
TLRs Toll-like Receptors  
TLR-4 Toll-like Receptor-4 
TNF-α Tumor Necrosis Factor 
UPR Unfolded Protein Response 
VEGF Vascular Endothelial Growth Factor  









List of figures 
Figure Title Page
Figure 1.1 Role of metabolic syndrome in the development of nonalcoholic 
fatty liver disease 
6 
Figure 1.2 Role of free fatty acids in the production of reactive oxygen 
species 
8 
Figure 2.1 Diagrammatic representation of hepatic regeneration experiment 22 
Figure 2.2 Diagrammatic representation of antibiotic/LPS/TAK-242 
treatment and kupffer cell reconstitution experiment 
24 
Figure 3.1 Consumption of unsaturated or saturated high fat diet led to 
hepatic steatosis both at week 16 and 32 
40 
Figure 3.2 Feeding with unsaturated or saturated high fat diet led to the 
development of NASH both at week 16 and 32 
42 
Figure 3.3 Mice fed unsaturated or saturated high fat diet showed the 
indication of fibrosis both at week 16 and 32 
44 
Figure 4.1 Unsaturated or saturated high fat diet led to the development of 
NASH in both resected and regenerated livers 
52 
Figure 4.2 Unsaturated or saturated high fat diet resulted in liver damage in 
both resected and regenerated livers 
53 
Figure 4.3 Hepatic regeneration following partial hepatectomy was impaired 
in mice fed unsaturated or saturated high fat diet. 
56 
Figure 5.1 Germ free mice fed high fat diet developed less hepatic steatosis 
compared to the specific pathogen free mice 
65 
Figure 5.2 Germ free mice fed high fat diet showed lower levels of NASH-
indicative markers in their livers compared to the specific 
pathogen free mice fed high fat diet 
67 
Figure 5.3 Germ free mice fed high fat diet showed decreased level of 
collagen accumulation in their livers compared to the specific 
pathogen free mice 
69 
Figure 5.4 Broad spectrum antibiotic-treated mice fed high fat diet 
developed similar level of hepatic steatosis compared to the 
control mice 
70 
Figure 5.5 Broad spectrum antibiotic-treated mice fed high fat diet showed 
decreased levels of NASH-indicative markers compared to the 
control mice fed high fat diet 
73 
Figure 5.6 Broad spectrum antibiotic-treated mice fed high fat diet showed 
decreased level of collagen accumulation in their livers compared 
to the control mice fed high fat diet 
74 
Figure 5.7 Reconstitution of gut microbiota in germ free mice fed high fat 
diet did not make any difference in the hepatic steatosis 
76 
Figure 5.8 Reconstitution of gut microbiota in germ free mice fed high fat 
diet showed elevated levels of NASH-indicative markers in their 
steatotic livers 
78 
Figure 5.9 Reconstitution of gut microbiota in germ free mice fed high fat 





Figure 5.10 Composition of gut microbiota changed in mice fed high fat diet 81 
Figure 5.11 Principal component analysis resulted in different clustering of 
mice fed high fat diet 
82 
Figure 6.1 Diminishing of gut microbiota resulted in reduced concentration 
of endotoxin in portal serum and feces 
90 
Figure 6.2 Injection of LPS or TLR-4 inhibitor in broad spectrum antibiotics-
treated mice fed high fat diet did not alter hepatic steatosis 
92 
Figure 6.3 Injection of low dose LPS in broad spectrum antibiotics-treated 
mice fed high fat diet resulted in increased level of NASH which 
was reversed upon administration of TLR-4 inhibitor 
94 
Figure 6.4 Injection of low dose LPS in broad spectrum antibiotics-treated 
mice fed high fat diet resulted in increased accumulation of 
collagen which was reversed upon administration of TLR-4 
inhibitor 
95 
Figure 6.7 TLR-4 KO mice fed high fat diet displayed similar level of hepatic 
steatosis as compared to the wild-type mice fed high fat diet 
97 
Figure 6.8 TLR-4 KO mice fed high fat diet exhibited decreased level of 
NASH which remained unchanged upon injection of low dose 
LPS 
99 
Figure 6.9 TLR-4 KO mice fed high fat diet displayed decreased level of 
collagen accumulation in their livers which remained unchanged 
upon injection of low dose LPS 
101 
Figure 6.10 TLR-4-expressing kupffer cells are involved in the accumulation 
of fat in mice fed high fat diet 
102 
Figure 6.11 TLR-4-expressing kupffer cells play crucial role in mediating 
NASH in mice fed high fat diet 
105 
Figure 6.12 TLR-4-expressing kupffer cells play an important role in collagen 
accumulation in the livers of mice fed high fat diet 
106 
Figure 6.13 Reconstituted kupffer cells in the livers of bone marrow recipient 
mice are derived from the transplanted cells 
108 
Figure 7.1 Fluorescence immunohistochemistry of peroxisomal membrane 
protein 70 in liver sections displayed a reduced level of 
fluorescence intensity in mice fed milk-based high fat diet in a 
TLR-4 dependent manner 
118 
Figure 7.2 Fluorescence immunohistochemistry of catalase in liver sections 
displayed a reduced level of fluorescence intensity in mice fed 
milk-based high fat diet in a TLR-4 dependent manner 
119 
Figure 7.3 Catalase level and activity are decreased in the livers of mice fed 









List of Tables 
Table Title Page
Table 1 List of Toll-like receptors and their microbial/non-microbial ligands 14 
Table 2.1 List of probes used for RT-PCR 30 
Table 2.2 List of antibodies used for immunoblot analyses 30 


































Nonalcoholic fatty liver disease (NAFLD) is defined as a condition with excessive 
fat accumulation and related complications in the liver of patients without any record of 
alcoholism [1].  Fat accumulation in the liver can also result from alcohol abuse which is 
called alcoholic fatty liver disease (AFLD) [2, 3].  NAFLD is an umbrella term which 
encompasses simple steatosis to nonalcoholic steatohepatitis (NASH) [4].  Hepatic 
steatosis refers to the normal accumulation of fat in the liver without or with minor 
inflammation.  Hepatic steatosis is benign, but long standing steatosis can lead to the 
development of NASH which is the advanced stage of NAFLD showing clear indication 
of chronic inflammation in the fatty liver [5, 6].    
Epidemiology of NAFLD and NASH 
NAFLD is a rapidly expanding health problem throughout the world. Currently, its 
global incidence is approximately 25% [7].  Variations in the incidence rate for NAFLD 
vary across the globe; the prevalence rate in Asia ranges from 5% to 18% and in Western 
countries from 20% to 30% [8].  Of the individuals with NAFLD, approximately  7% to 30% 
meet the clinical criteria for NASH [9].  Here in the USA, the prevalence rate for NAFLD 
is 30%, with 25% of them satisfying the clinical definition of NASH.  Thus, an overall 
incidence rate for NASH within the US population is approximately 3-8% [10-13]. 
Risk of progression of NASH to end stage liver diseases 
A major concern for individuals with NASH is the likelihood of their progression to 
end stage liver diseases, that will ultimately require transplantation [14].  The potential of 
NASH to progress into fibrosis and hepatocellular carcinoma is recognized.  Alarmingly, 
it has been projected that NASH is going to become the leading cause of liver related 
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morbidity and mortality [15-18].  Although the patients with NASH are at greater risk, 
individuals with simple steatosis and mild inflammation can also progress to fibrosis and 
hepatocellular carcinoma [4, 5, 19-21].  Hepatic fibrosis is defined as an excessive 
deposition of extracellular matrices, especially collagen, within the liver.  While hepatic 
fibrosis results in only minor clinical complications and/or hepatocyte dysfunction, it is 
considered a predictor that the patient has a greater risk of developing cirrhosis [22]. 
Hepatocellular carcinoma is considered the fifth most common cancer and third leading 
cause of cancer-related death in the United States [23].  Hepatitis C virus, alcohol-related 
liver diseases, and hepatitis B virus have been implicated as the three leading causes of 
hepatocellular carcinoma in the western world [24].  A role for NASH in this demographic 
has been underestimated.  However, an increasing prevalence of NASH-related 
hepatocellular carcinoma predicts that NASH is going to become the leading cause of 
hepatocellular carcinoma in the Western countries in near future [10, 24].  Given the 
epidemiological data with respect to NASH and its role in end stage liver diseases, 
approaches to curb the transition from NAFLD to NASH is paramount if we wish to 
improve the morbidity and mortality of patients afflicted with a steatotic liver. 
From metabolic syndrome to NASH 
The etiology of NASH is closely associated with metabolic syndrome [1, 4].  
According to the World Health Organization, metabolic syndrome is a condition 
characterized by multiple metabolic abnormalities including obesity, insulin resistance 
and type-2 diabetes mellitus [25].  Diet and a sedentary life style have been implicated in 
the development of metabolic syndrome.  In the latter half of the 20th century with the 
emergence of a sedentary ‘corporate professional life-style’ and ‘fast food culture’ 
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(containing high fat, carbohydrate, and calories), Westerners  are now considered to have 
a greater risk for developing metabolic syndrome than the people in developing countries 
where manual labor is still the norm for the bulk of the population [26-28].   
Obesity is strongly associated with an increased risk of developing NAFLD.  
Prevalence rate of NAFLD increases with an increase in body mass index [29, 30].  
Incident rates of hepatic steatosis and NASH have been observed to occur respectively 
at 95% and 20% in obese patients [9].  Fat deposition in the liver is directly correlated 
with the accumulation of visceral adipose tissue. Mesenteric fat, a specific type of visceral 
adipose tissue, is drained into the liver through portal circulation, leading to the deposition 
of fat droplets causing hepatic steatosis [31, 32].  
Insulin resistance is a common condition observed in individuals with metabolic 
syndrome. Insulin resistance results in impaired glucose uptake and disposal, an increase 
in de novo synthesis of fatty acids, and an inadequate level of free fatty acid oxidation 
[33, 34].  Therefore, insulin resistance leads to the increased level of free fatty acids, 
adding to the accumulation of fat in the liver [35].  
As a mechanism, insulin action on the liver is coordinated between hepatocytes 
and adipose tissue.  In hepatocytes under a normal condition, insulin signaling pathways 
result in a decreased expression of gluconeogenic enzymes, an inactivation of glycogen 
synthase kinase 3β resulting in an activation of glycogen synthase, and improved rates 
of glycolysis and mitochondrial oxidative phosphorylation.  A decrease in the expression 
of gluconeogenic enzymes and activation of glycogen synthase results in reduced free 
glucose formation.  Reduced level of free glucose indirectly inhibits the de novo synthesis 
of fat by limiting the availability of precursor compounds [36, 37].  
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In adipose tissues under a normal condition, insulin signaling suppresses lipolysis 
which in turn decreases the supply of free fatty acids and glycerol into the liver resulting 
in a reduced formation of fat droplets.  A reduced supply of glycerol into the liver inhibits 
gluconeogenesis through the reduced conversion of glycerol to glucose [38-40].   
In contrast to the insulin signaling in a normal condition, insulin resistance 
constrains hepatic glycogen synthesis leading to an excess of free glucose.  Insulin 
resistance in adipose tissue impedes insulin-mediated suppression of lipolysis leading to 
increased delivery of free fatty acids and glycerol into the liver [36, 41-45].  Insulin 
resistance in the liver leads to an elevated level of free glucose. Elevated level of free 
glucose is correlated with altered adipose lipid metabolism resulting in an increased 
supply of free fatty acids and glycerol [46-50].  Therefore, insulin resistance mediates a 
complex, reciprocal form of feedback between adipose tissue and the liver leading to 
hepatic steatosis.  
Type-2 diabetes mellitus (T2DM) is the most studied metabolic disorder with an 
occurrence of insulin resistance and inability of pancreatic beta cells to produce sufficient 
insulin to address the phenomenon of insulin resistance, [51].  The prevalence of NAFLD 
has been linked to T2DM.  In one study, it was reported that the prevalence of NAFLD in 
obese patients with T2DM was 70% higher than in obese patients without T2DM [52].    
These data taken collectively suggest that a close association exists between metabolic 
syndrome and NAFLD [53].  Obesity, insulin resistance and T2DM are interrelated in 











Figure 1.1. Role of metabolic syndrome in the development of nonalcoholic fatty liver disease.  
Excessive consumption of fat in concert with a sedentary lifestyle result in metabolic syndrome as 
manifested by obesity, insulin resistance and type-2 diabetes mellitus. Insulin resistance plays the 
pivotal role of metabolic syndrome in causing an increased level of free fatty acids in the liver through 




A ‘Two-hit hypothesis’ to explain the pathogenesis of NASH 
The pathogenesis of NASH has yet to be fully elucidated.  Currently, it is explained 
by a  ‘two-hit hypothesis’ originally proposed by Day and James [54].  According to this 
hypothesis, the first hit results from the accumulation of excessive fat leading to ‘hepatic 
steatosis’.  A liver is considered steatotic if it contains more than 5% to 10% fat [55].  
Hepatic steatosis is phenotypically unremarkable, but a long-term steatosis can result in 
the second hit caused by oxidative stress, dyslipidemia, mitochondrial dysfunction, an 
altered cytokine milieu, immune infiltrations, and endoplasmic reticulum stress [56].  
Subsequent to the second hit, the transition of the steatotic liver occurs from being 
pathologically benign to a state where the organ is chronically inflamed [56]. 
Pro-inflammatory mediators of NASH 
Oxidative stress, endoplasmic reticulum stress and hepatocyte apoptosis are 
considered key pro-inflammatory mediators of NASH [56].  The concentration of free fatty 
acids within hepatocytes is low in the normal condition.  An increased influx of free fatty 
acids into the hepatocytes initiates chronic inflammation within the liver.  This increased 
influx of free fatty acids can result from 1) the consumption of a diet rich in carbohydrates 
or fat, 2) the lipolysis of stored fat, or 3) the de novo synthesis of fatty acids [56-58].  Such 
an increase in the availability of free fatty acids within the hepatocytes results in an 
increased fatty acid oxidation in mitochondrial and extra-mitochondrial sites leading to the 
over-production of reactive oxygen species (ROS).  An excess production of ROS creates 
an imbalance with antioxidants, which in turn leads to oxidative stress and mitochondrial 








Figure 1.2. Role of free fatty acids in the production of reactive oxygen species. Free fatty acids 
can be directly transported into the liver from diet via chylomicrons. Free fatty acids can also be 
delivered from the lipolysis of adipose tissues. They can also be synthesized de novo from diet-derived 
carbohydrates. Free fatty acids are incorporated into triglycerides which are then accumulated into 
lipid droplets leading to hepatic steatosis. Excess free fatty acids undergo fatty acid oxidation in 
mitochondrial and extra-mitochondrial sites especially peroxisomes. Increased fatty acid oxidation in 
hepatocytes leads to the elevated level of reactive oxygen species resulting in oxidative stress which 
is the key initiator of steatohepatitis.   
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The presence of excess free fatty acids within hepatocytes can also lead to an 
overload of lipids in the endoplasmic reticulum (ER), resulting in ER dysfunction. ER 
dysfunction results in the accumulation of unfolded and/or misfolded proteins manifested 
as ER stress [61].  Mitochondrial dysfunction and ER stress culminate in the apoptosis of 
hepatocytes, leading to the activation of hepatic innate cells and pro-inflammatory 
immune infiltrates [59-62].  
Gut microbiota and their contribution to human health 
In addition to the consequences associated with free fatty acid-mediated oxidative 
and ER stress, the role of other endogenous and exogenous mediators of NASH are of 
interest.  One area receiving significant attention is the role that gut microbiota plays in 
the onset of NASH, but further investigation is required to have a better picture on the 
mechanistic role of gut microbiota in mediating NASH.  Bacterial cells living inside and 
outside the human body outnumber the host eukaryotic cells [63].  The majority of these 
microbes reside within the gastrointestinal tract due to favorable growth conditions and 
the continuous influx of nutrients.  It has been estimated that the total number of microbes 
harbored in the gastrointestinal tract collectively make up to 100 trillion microbes which is 
ten-fold higher than the human cells [64].  The unique gastro-intestinal niche confers 
increased fitness and stability to the microbes through their continuous communication 
and interactions with the host [65]. A tremendous number of studies have suggested that 
the gut microbiota plays a critical role in the control and onset of human health and 
disease.  For instance, gut microbiota has an essential role in energy homeostasis and 
nutrient recovery from ingested diets.  The microbial genes from the collective microbial 
community provide unique enzymes required for specific biochemical pathways [66, 67].  
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These enzymes have essential roles in the metabolism of xenobiotics, undigested 
carbohydrates and the biosynthesis of vitamins and cofactors essential to the host [67, 
68].  Significantly, the gut microbiota generates short chain fatty acids that are used as 
an energy source by the gut epithelial cells.  These short chain fatty acids have an 
important role in regulating gut motility and inflammation [69-71].  The gut microbiota also 
serve an important role in providing a barrier to pathogens through competitive exclusion 
and production of antimicrobial substances [67, 72-74].  
Additionally, the gut microbiota has an essential role in the development of the 
immune system of the host. It has been reported that there are an abnormal number of 
immune cells and perturbations to the cytokine milieu in the lymphoid organs of germ free 
mice [67, 75].  Depletion of gut microbiota in mice has been shown to result in the 
depression of immunity and an abnormally reduced immune infiltrates in the gut [76].  Due 
to a direct communication between the liver and gut, it is assumed that gut microbiota 
may be responsible for the maintenance of intestinal health, which in turn may have an 
impact on the overall function of the liver. 
Dynamic composition of gut microbiota and metabolic syndrome 
Compositional changes to the gut microbiota have been observed secondary to 
environmental, immunological, dietary and/or nutritional alteration experienced by the 
host.  Such compositional changes have been associated with various host pathologies, 
including metabolic syndrome [77-83].  Our understanding of the factors affecting the 
composition of gut microbial community and how such changes can alter the risk of 
metabolic disease in mammals was first attributed to studies conducted by Jeffrey Gordon 
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and his group [84-86].  They showed that changes to the gut microbiota are secondary to 
diet-induced obesity in mice.  These changes significantly influence energy harvest from 
diet, its utilization, and storage [86-88].  Apart from these studies in animal models, 
changes to the gut microbiota in obese humans have been reported by Ley and 
colleagues [89].  They showed that the proportions of Bacteroidetes to Firmicutes was 
decreased in the gut of obese patients as compared to the lean controls.  In concert with 
obesity, dysbiosis was also observed in the metabolic syndrome manifested by T2D.  
Reduced proportions of the phylum Firmicutes and class Clostridia in concert with higher 
proportions of beta-proteobacteria were observed in patients with T2D compared to 
healthy individuals [79].  Positive correlations have occurred with the concentration of 
glucose observed in human plasma and the ratio of Bacteroidetes to Firmicutes as well 
as the ratio of Bacteroides-Prevotella group to Clostridium coccoides-Eubactereium 
rectale group [79].  These data suggest a potential association of T2D with compositional 
changes to the microbial community within the human gut.  Due to the close relationship 
between metabolic syndrome and NASH, similar changes to the composition of gut 
microbiota are anticipated in patients with NASH. 
Gut microbiota bridges gut-liver axis 
The term ‘gut-liver axis’ was first proposed by Volta and colleagues in 1978 [90]. 
Since then, a substantial number of studies have evaluated the association between the 
gut and liver  in concert with human health and diseases [91].  In a healthy state, the gut 
epithelial layer selectively allows the entry of nutrients, ions and water across the gut 
epithelial boundary while simultaneously excluding deleterious compounds and microbes.  
The gut microbiota serves to protect the epithelial layer from pathogens through 
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competitive exclusion and production of pathogen specific antimicrobials. In addition to 
providing a protective layer to exclude pathogens, the gut microbiota serves an important 
role in maintaining a healthy epithelial barrier.  The gut microbiota generates acetate, 
propionate and butyrate which contribute to maintain a tight epithelial barrier [92-94].   
Consequently, any change to the gut microbiota that alters the delicate balance to 
epithelial nutrients may potentially compromise epithelial integrity, resulting in a condition 
termed leaky gut [95].  During this abnormal circumstance, the gut epithelial layer will 
demonstrate an impaired ability to regulate the entry of waste and other toxic components 
into the circulation.  A leaky gut has been observed in patients with NAFLD [95, 96]. All 
gut-derived components crossing the epithelial barrier are drained into the liver through 
portal circulation.  Therefore, a leaky gut poses a potential threat to the liver by increasing 
the supply of pro-inflammatory gut microbes-derived compounds into an organ that is 
already susceptible to inflammation secondary to an excessive accumulation of fat [97, 
98]. 
Gut microbiota induces pro-inflammatory pathways through the interaction with 
toll-like receptors  
Toll-like receptors are pattern recognition molecules expressed by a variety of 
professional and non-professional immune cells.  Toll receptor was originally identified in 
Drosophila melanogaster as a molecule essential to determine the dorsal-ventral axis 
orientation during embryogenesis [99].  Subsequently, human homologues were 
discovered and named Toll-like receptors (TLRs) [100, 101].  The intracellular domains 
of TLRs have similarity to the interleukin-1-receptor (IL-1R) known as Toll/Interleukin-1 
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receptor (TIR) domain.  The function of TIR domain is to recruit adaptor molecules that in 
turn pass the signal upon the binding of ligands to the TLRs.  
TLRs recognize microbe associated molecular patterns (MAMPs) and are 
responsible for the induction of pro-inflammatory responses.  In addition to microbial 
components, TLRs can also recognize endogenous ligands known as danger associated 
molecular patterns released from damaged tissue, infected tissue or dead cells.  Upon 
the binding of ligand to the extracellular domain of TLRs, adaptor molecules are recruited 
to the cytoplasmic TIR domain resulting in a sequential activation of intracellular signaling 
molecules called signal transduction.  The consequence of signal transduction is the 
activation of transcription factor nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-κB), which results in an expression of pro-inflammatory mediators such as 
cytokines and chemokines.  In addition to activating the NF-κB pathway, mitogen 
activated protein kinase cascades are also activated by the TLR-ligand interaction [100, 
102, 103].  TLRs were initially considered only to induce anti-pathogen inflammatory 
responses, but growing body of evidence indicates that activated TLRs are the underlying 
cause for a number chronic inflammatory diseases (Table 1) [100, 103-112]. 
Potential role of low grade chronic endotoxemia in metabolic syndrome 
The gut microbiota contains both Gram-positive and Gram-negative bacteria. 
Lipopolysaccharide (LPS), also known as endotoxin, is a major outer membrane 




TLRs Microbe-derived ligands Nonmicrobial ligands Diseases 
 Ligands Sources   
 TLR-1/2/6 Triacyl lipopeptides Bacteria Fatty acids Atherosclerosis 
 Peptidoglycans  Gram-positive bacteria Hyaluronan fragments Inflammatory 
bowel disease 
 Phenol soluble modulin Staphylococcus aureus HMGB-1 Asthma 
 Glycolipids Treponema maltophilum HSPs Rheumatoid 
arthritis 
 Atypical LPS Non-entero bacteria   
 Phospholipomannan Candida albicans   
 LPG Leishmania major   
 Tc52 Trypanosoma cruzi   
 Diacyl lipopeptides Mycoplasma   
 Lipoteichoic acid Gram-positive bacteria   
 Zymosan Saccharomyces cerevisiae   
 GPI anchor Trypanosoma cruzi   
 Envelope protein Measles virus   
  Human cytomegalovirus   
  herpes simplex virus type I   
TLR-3 dsRNA Viral dsRNA Synthetic dsRNA 
(Poly(I:C) 
Type 1 diabetes 
    Rheumatoid 
arthritis 
TLR-4 LPS Gram-negative bacteria Fatty acids Atherosclerosis 
 Mannan Saccharomyces cerevisiae Hyaluronan fragments Multiple sclerosis 
  Candida albicans HMGB-1 Asthma 
 Glucuronoxylomannan Cryptococcus neoformans HSPs Rheumatoid 
arthritis 
 F protein Respiratory syncytial virus Fibronectin fragments  
 Envelope protein Mouse mammary tumor virus   
 











TLR-5 Flagellin Flagellated bacteria  Inflammatory bowel 
disease 




    Type 1 diabetes 
TLR-9 CpG DNA  Bacteria Immune complexes/dsDNA Systemic lupus 
erythematosus 
  Virus  HMGB-1 Type 1 diabetes 
 Genomic DNA Babesia bovis  Multiple sclerosis 
  Trypanosoma cruzi  Inflammatory bowel 
disease 
  Trypanosoma brucei  Rheumatoid arthritis 
 Hemozoin Plasmodium falciparum   
TLR-11 Not determined Uropathogenic bacteria   
 Profilin-like protein  Trypanosoma gondii   




bacteria either through their lysis or growth [113, 114].  Although the presence of LPS is 
restricted to the intestinal lumen [115], small amounts of LPS can pass through the 
epithelial barrier and enter the circulation in healthy individuals [116].  While the presence 
of LPS in circulation is normal, an increased concentration can result in chronic 
endotoxemia.  Thus, the role of an increased concentration of gut-derived LPS in blood 
circulation is an important topic of investigation in relation to chronic inflammatory 
diseases, in particular, the metabolic syndrome. 
Inflammatory responses associated with acute endotoxemia, secondary to sepsis, 
have revealed alterations to lipid metabolism [117, 118].  A lethal or sub-lethal dose of 
endotoxin in mice leads to increased adipose lipolysis resulting in an elevated 
concentration of circulating free fatty acids [119-121].  Despite an increased level of 
circulating free fatty acids, fat accumulation in the liver is prevented due to the autophagy 
induced by a lethal dose of endotoxin [120].  In contrast to acute endotoxemia, our 
understanding of the pro-inflammatory consequences associated with a low 
concentration of circulating LPS and its impact on lipid metabolism is still unclear.  
Recently, Cani and colleagues have observed that a low concentration of endotoxin is 
increased in obese (ob/ob) mice and in lean mice fed a high fat diet.  They have shown 
that a chronic elevation to the concentration of endotoxin through the infusion of low grade 
LPS results in fat deposition in adipose tissue, which is in direct conflict to observations 
associated with the animals exposed to acute endotoxemia [122, 123].  Moreover, plasma 
levels of LPS have been reported to increase in patients with abdominal obesity 
compared to the healthy controls, which is in line with the observations associated with 
mice exposed to chronic endotoxemia [124].  
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TLR-4 pathway is essential in the modulation of metabolic syndrome 
LPS interacts with TLR-4 upon binding to CD14 to induce inflammation [125].  Cani 
and colleagues have shown that CD14 knockout mice are partially protected from a high 
fat diet-induced increase in adipose tissue and body weight [122, 123].  This study 
suggested a role for the TLR-4 pathway in metabolic derangements in high fat diet-
mediated obesity in mice [123].  The TLR-4 pathway has also been linked to metabolic 
syndrome in human patients.  Creely et al. have shown that the expression level of TLR-
4 is higher in obese and in type-2 diabetes patients compared to healthy individuals [126].  
Potential role of LPS-TLR-4 axis in NASH 
In human, the liver is the first organ to encounter LPS delivered from the gut 
microbial community. TLR-4 expressing Kupffer cells are a major and well characterized 
target of LPS in the liver to execute the subsequent pro-inflammatory events [127, 128].  
In comparison to healthy individuals, a slightly elevated level of serum endotoxin was 
reported in NASH patients which led to investigations examining the potential role of low 
dose LPS in driving inflammation in NASH in experimental models [129-132].  Indeed, 
injection of subclinical dose of LPS in mice fed high fat diet or obese mice (ob/ob) resulted 
in exacerbated hepatic inflammation indicating the role of chronic endotoxemia in causing 
NASH [133].  Based on these reports, a comprehensive study to investigate the role of 
LPS-TLR-4 axis in causing chronic inflammation in the fatty liver is needed.  Therefore, 
in this project, we attempted to establish the role of gut-derived LPS-TLR-4 pathway as 
an actual risk factor to sustain a chronic inflammation during the pathogenesis of NASH. 
We also attempted to employ the LPS-TLR-4 pathway as a potential target for therapeutic 






















Our initial objective was to investigate the global involvement of gut microbiota in 
causing NASH.  This objective was experimentally addressed by using specific pathogen 
free and germ free mice.  We also conducted gut microbiota reconstitution 
(conventionalization) experiment to test whether the restoration of gut microbiota in germ 
free mice through fecal transfer from normal mice could impact the level of NASH.  We 
then intended to assess the role of LPS-TLR-4 pathway in mediating NASH by using wild-
type and TLR-4 KO mice individually treated with broad-spectrum antibiotics, LPS, or 
TLR-4 inhibitor.  Bone marrow transplantation experiment was performed to investigate 
the role of TLR-4-expressing kupffer cells in the modulation of NASH.  Following 
euthanization, tissue samples were collected for subsequent analyses.  In this chapter, 
different experimental steps and methods used in this project have been described with 
detailed information in a reproducible manner. 
Animal experiments 
Six-week-old male wild-type C57BL/6 mice were purchased from Jackson 
Laboratories and maintained under specific pathogen free conditions.  Six-week-old germ 
free male C57BL/6 mice were bred and housed in flexible plastic gnotobiotic isolators 
following a strict 12 h light cycle at the gnotobiotic animal research facility of the Medical 
University of South Carolina.  Six-week-old toll-like receptor knock out (TLR-4 KO) 
C57BL/6 male mice were purchased from Jackson Laboratories and maintained under 
specific pathogen free conditions.  After two weeks of equilibration on normal chow, the 
now eight-week-old mice were placed either on an isocaloric control diet ((CD), TD.08810, 
10% kcal from fat), a lard-based high fat diet ((LD), TD.06414, 60% kcal from fat, 63% 
unsaturated) or a milk-based high fat diet ((MD), TD.09766, 60% kcal from fat, 61% 
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saturated), purchased from Harlan Laboratories (IN, USA).  Mice were housed at 22 °C 
with 12 h light/dark cycle, fed special diets for 8, 16 or 32 weeks ad libitum and weighed 
each week.   After 8, 16, or 32-weeks of feeding, they were euthanized whereupon the 
liver were harvested and blood samples were collected.  Whole livers were weighed with 
portions of them processed for the isolation of total RNA and subsequent analysis for 
specific proteins.  The remaining fraction of the liver was fixed in 10% neutral buffered 
formalin (Starplex Scientific Inc., Ontario, Canada) for 24 h at room temperature, with its 
subsequent embedding into paraffin, sectioning, and histological/immunohistochemical 
staining.  All of the animal studies were reviewed and approved by the Medical University 
of South Carolina’s Institutional Animal Care and Use Committee (IACUC).  
For conventionalization (restoration of normal gut flora) experiment, gut microbiota 
was reconstituted in six-week old germ free mice fed CD or MD by fecal transplantation 
from specific pathogen free wild-type donor mice.  Stool from donor mice were diluted in 
saline (0.1g/mL) and gavaged into germ free animals on a weekly basis for a period of 16 
weeks (200 µL per animal).  The remaining stool solution was placed on the fur of the 
animals.  Part of soiled bedding was collected from the cages of stool donors and placed 
into the cages of the conventionalized/recipient animals on the same weekly schedule.   
Partial hepatectomy 
Partial hepatectomy experiment was performed to investigate the role of dietary 
fat-mediated NASH on hepatic regeneration.  After 16 weeks of continuous feeding with 
CD, LD or MD, C57BL/6 mice were anesthetized with isoflurane and subjected to a mid-
ventral laparotomy with approximately 70% of liver resection (left lateral and median lobes 
hereafter referred to as resected lobes) [134].  Animals from individual diet interventional 
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and control group were sacrificed 2 or 7 days post-hepatectomy.  One hour prior to 
sacrifice, a single dose of 5-bromo-2'-deoxyuridine (BrdU, Sigma-Aldrich, MO, USA) was 
injected intraperitoneally at a dose of 50 mg/kg animal weight using a vehicle of 0.2% 
pyrogen free phosphate buffered saline (Fig. 2.1).  At the time of sacrifice, animals were 
anesthetized with isoflurane and total blood was harvested from the right ventricle of the 
heart.  The remaining lobes of the liver, hereafter referred to as regenerated lobes, were 
harvested.  Both of the resected and regenerated lobes of the livers were weighed and 
were processed for RNA, protein and histological analyses. 
Treatment with broad-spectrum antibiotic, LPS and TLR-4 inhibitor 
It was intended to investigate the role of LPS in causing NASH as a sole gut-
derived molecule present in the circulation.  To ensure that chronic inflammation was not 
induced by any gut-derived component other than LPS, gut microbiota was diminished by 
the treatment of broad spectrum antibiotics followed by the chronic administration of low 
dose LPS.  Broad spectrum antibiotics-treated and LPS-injected mice were administered 
with TLR-4 inhibitor to demonstrate the role of TLR-4 pathway in causing NASH.  To 
accomplish this experiment, specific pathogen free, C57BL/6 mice fed CD or MD for 16 
weeks were treated with ampicillin (1 g/l: Sigma-Aldrich, USA), neomycin sulfate (1 g/l: 
Sigma-Aldrich, USA), metronidazole (1 g/l: Sigma-Aldrich, USA) and vancomycin (500 
mg/l: Sigma Aldrich, USA) ad libitum through the drinking water.  During the last four 
weeks of antibiotic treatment, the mice were injected intraperitoneally daily with 0.25 
mg/kg body weight LPS (O55:B5, Sigma Aldrich, USA) or vehicle (0.9% saline).  During 
LPS injection, mice were also injected intraperitoneally three times per week with 3 mg/kg 










Figure 2.1. Diagrammatic representation of hepatic regeneration experiment.  Mice fed control diet or milk-
based high fat diet for 16 weeks were subjected to partial hepatectomy. After 2 or 7-days of partial hepatectomy, 
mice were injected with BrdU one hour prior euthanization. CD and MD indicate control diet and milk-based high 
fat diet, respectively. 
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TLR-4 KO mice fed CD or MD were injected with LPS using same protocol as mentioned 
above (Figure 2.2A).  
Bone marrow transplantation and depletion of kupffer cells  
To investigate the role of TLR-4-expressing kupffer cells in mediating NASH, an 
experiment was designed where kupffer cells in the livers of wild-type mice were 
reconstituted with TLR-4 KO cells and kupffer cells in the livers of TLR-4 KO mice were 
reconstituted with wild-type cells.  To accomplish this experiment, 8x106 bone marrow 
cells, obtained from wild-type or TLR-4 KO mice, were injected into tail vein of lethally 
irradiated (11 Gy) TLR-4 KO or wild-type mice respectively.  After 2 weeks of bone marrow 
transplantation, mice were injected intravenously just once with 200 µl of 5 mg/mL of 
liposomal chlodronate (Encapsula NanoSciences, USA). Injection of chlodronate 
depleted the former kupffer cells resident in the liver and served to create an available 
niche for the transplanted bone marrow-derived monocytes to settle as new kupffer cells.  
After 10 weeks of chlodronate injection (during this 10 weeks mice were on regular chow 
provided by the animal facility), both the wild-type and TLR-4 KO mice were fed CD or 
MD for 16 weeks (Figure 2.2B) [135].   
A question was raised whether the engrafted hematopoietic cells-derived 
monocytes were actually settled as kupffer cells in the livers. Following experiment was 
performed to answer this question using CD45.1 (donor) and CD45.2 (recipient) congenic 
mice.  8x106 bone marrow cells isolated from CD45.1 donor mice were intravenously 
injected into lethally irradiated (11 Gy) congenic CD45.2 recipient mice.  Following 2 









Figure 2.2. Diagrammatic representation of (A) antibiotic/LPS/TAK-242 treatment and (B) kupffer cell 
reconstitution experiment. (A) Broad spectrum antibiotics-treated mice fed CD or MD for 16 weeks were injected with 
LPS or administered with TAK-242 for last 4 weeks of experiment. (B) Lethally irradiated TLR-4 KO or wild-type mice 
were transplanted with bone marrow isolated from wild-type or TLR-4 KO mice. After 2 weeks of bone marrow 
transplantation, mice were injected with liposomal chlodronate. Following 10 weeks of liposomal chlodronate injection, 
mice were fed control diet or milk-based high fat diet for 16 weeks. CD and MD indicate control diet and milk-based high 
fat diet, respectively. 
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chlodronate (200 µl of 5 mg/mL).  After 10 weeks of chlodronate injection, non-
parenchymal cells were isolated from the livers of chimeric and control mice and used for 
flow cytometric analyses. 
ALT and AST assays 
 Presence of alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) in the serum was determined as an indicator of NASH.  After the collection of whole 
blood through heart puncture, it was allowed to clot by leaving undisturbed at room 
temperature for 15–30 min.  The clot was removed by centrifuging at 1,000–2,000x g for 
10 minutes at 4°C.  Following centrifugation, the transparent yellowish liquid component 
(serum) was immediately transferred into a clean polypropylene microcentrifuge tube and 
stored at -20 °C [136].  Serum was assessed for the presence of ALT and AST using 
standard kit protocols provided by the manufacturer (BioVision Inc., USA).  
Endotoxin assays  
In order to assess the concentration of circulating endotoxin, serum was collected 
from the portal blood following the protocol used for serum collection from the whole blood 
[136].  Portal serum was used to determine the concentration of LPS using the Pierce 
Limulus Amebocyte Lysate (LAL) chromogenic endotoxin assay kit following standard 
protocol provided by the manufacturer (Thermo Scientific, USA).  
In order to assess the concentration of endotoxin resident in the fecal material of 
the animals, 20 mg of fecal matter was collected from the cecum of each animal 
whereupon it was placed into 50 mL PBS within a pyrogen-free tube.  The material was 
then sonicated at 20 KHz for 1 h on ice.  Subsequent to sonication, the resulting material 
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was centrifuged at 400 × g for 15 min.  The upper 30 mL of the sonicate was collected, 
sterilized by filtration through a 0.45-μm filter, re-filtered through a 0.22-μm filter, and 
inactivated for 10 min at 70°C [137].  The LPS concentration present in the  filtered 
sonicate was determined using  the Pierce Limulus Amebocyte Lysate (LAL) chromogenic 
endotoxin assay kit following standard protocol provided by the manufacturer 
(ThermoFisher Scientific, USA). 
Liver histology and immunohistochemical staining 
In order to assess the histopathological status of NAFLD, formalin fixed and 
paraffin-embedded (FFPE) tissues were evaluated.  The 5 µm FFPE sections were 
stained with Hematoxylin and Eosin (Richard-Allan Scientific® Histology/Cytology 
Reagents, ThermoFisher Scientific, USA) using the standard protocol provided by the 
manufacturer.  Slides were assessed for the extent to which each liver sample met the 
criteria for NAFLD.  This evaluation was performed by an experienced liver pathologist 
using an established semi-quantitative schema [138-140].  In brief, NAFLD activity was 
determined from the sum of the total steatosis observed, the extent with which lobular 
inflammation was present and the level of hepatocellular ballooning.  Levels of steatosis 
were scored as a percent area of the field occupied by the empty spots secondary to the 
release of fat droplets as a consequence of ethanol wash during the paraffin embedding.  
Lobular inflammation was scored from the level of cellular infiltration and hepatocellular 
ballooning was scored from the number of enlarged hepatocytes with rarefied cytoplasm 
that achieved a size greater than 1.5 to 2 times the diameter of a normal cell [138-140].  
In order to visualize the deposition of fat within the liver, liver tissues were 
embedded in optimal cutting temperature (O.C.T) compound. The 5 µm O.C.T sections 
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were stained with oil red O (Sigma-Aldrich, USA) using the standard protocol provided by 
the manufacturer [141].  Oil red O-stained O.C.T sections were visualized and imaged 
using ZEISS Axiovert 200M inverted microscope equipped with a digital camera (20x 
magnification). 
In order to assess the level of collagen accumulation, 5 µm FFPE liver sections 
were stained with picrosirius red.  Briefly, FFPE sections were deparaffinized in xylene, 
whereupon they were rehydrated by serially soaking in 100%, 95%, 90% and 0% ethanol 
and then incubated in a solution of 0.1% Sirius red (Direct red 80, Sigma-Aldrich, USA) 
and 1.3% saturated picric acid (Sigma-Aldrich, USA) for 1 hour. Subsequent to staining, 
the sections were washed using a 0.5% acetic acid solution, whereupon they were 
dehydrated by serially soaking in 0%, 90%, 95% and 100% ethanol and xylene.  
Picrosirius red-stained sections were imaged using ZEISS Axiovert 200M inverted 
microscope equipped with a digital camera (20x magnification). 
Hepatocyte nuclear staining for BrdU was performed by using BrdU 
immunohistochemistry kit essentially as described by the manufacturer (abcam, USA).  
BrdU-incorporated hepatocytes were counted in high-power field of light microscope 
using 20x magnification and expressed as a percentage of total hepatocytes (both BrdU 
stained and non-stained). 
The number of neutrophils present in each FFPE section was determined by 
staining the sections with Leder stain (Napthol AS-D chloroacetate esterase, Sigma-
Aldrich, USA).  The number of infiltrating neutrophils was determined by counting the 
number of Leder-positive cells encountered in each high-power field (20x magnification) 
from each section evaluated.   
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The number of macrophages present in each FFPE section was determined by 
immunostaining for F-4/80.  FFPE sections were incubated in 0.3% H2O2 for 30 min to 
quench the activity of endogenous peroxidase followed by an incubation with primary 
antibody (rat anti-mouse F4/80, clone BM8, Biolegend, USA) and secondary antibody 
using Vectastain ABC kit (Vector Laboratories, USA) following the standard protocols 
provided by the manufacturers. The percentage of macrophage infiltration was 
determined as the number of positively stained macrophages against the total number of 
cells present in each high power field (20x magnification) per section [142]. 
In order to do fluorescence immunohistochemistry, FFPE sections were boiled in 
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 30 min for 
antigen retrieval followed by the blocking with 5% BAS for 30 min at room temperature, 
overnight incubation with the primary antibody at 4°C, 1.5 hour incubation with secondary 
antibody, and DAPI staining following standard protocol (abcam, USA).    
Quantitative real time reverse transcriptase polymerase chain reaction (RT-PCR)  
Expression levels of different NASH-indicative genes were determined by using 
RT-PCR.  Total RNA was isolated from 20-50 mg liver tissue using Trizol (Ambion, USA) 
according to the manufacturer’s instructions.  The concentration of RNA recovered was 
determined by Nanodrop Spectrophotometer (ThermoFisher Scientific, USA).  The quality 
of RNA was assured by determining the ratio of absorbance at 260 nm and 280 nm.  A 
ratio of absorbance at 260 nm and 280 nm higher than 2.0 confirmed the purity of RNA 
samples [143].  The concentrations of RNA between samples were equalized through 
dilution using sterile, RNase free water.  
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RT-PCR was accomplished by taking 500 ng of RNA, subjecting it to reverse 
transcription with subsequent amplification of the DNA template using LightCycler 480 
instrument (Roche, USA) using the TaqMan Fast Virus 1-step PCR master mix (Applied 
Biosystems, USA) and TaqMan-FAM-MGB primers/probes (Applied Biosystems, USA) in 
a final reaction volume of 20 µL using the following thermocycling profile.  1) Reverse 
transcription at 50°C for 5 min; 2) inactivation of the reverse transcriptase by exposing the 
reaction to 95°C for 20 sec;  and 3) amplification of newly transcribed DNA template with 
40 successive cycles at 60°C for 30 seconds followed by denaturation at 95°C.  Gene-
specific probe information are provided in Table 2.1.  The expression level of a given gene 
was calculated as a fold difference in relative to the normalized expression level 
housekeeping gene HPRT1 using the comparative ∆∆Ct method [144]. 
Western blot analysis 
Differences in the expression level of different NASH-associated proteins in the 
liver were assessed by using Western blot analysis.  In order to prepare tissue 
homogenate, 50 mg of liver tissue was homogenized in 200 µL of RIPA buffer (25 mM 
Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS and 5% 
mammalian proteinase inhibitor) (Sigma-Aldrich, USA) [145].  Protein concentration in the 
tissue homogenate was determined by following the instruction of BCA assay kit (Pierce, 
USA).  Then, 5 µg of protein samples were run on 4-12% NuPage polyacrylamide gels 
(Life Technologies, USA) and transferred to nitrocellulose membrane (ThermoFisher 
Scientific, USA).   After blocking with TBS-T (Sigma-Aldrich, USA) containing 5% milk for 
30 min, blots were incubated overnight at 4°C with the primary antibody diluted in TBS-T 
containing 5% milk [146].  The blots were then washed with TBS-T, incubated with 
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peroxidase-conjugated secondary antibody diluted in TBS-T containing 5% milk for 1.5 hr 
at room temperature (information about the antibodies used in Western blot analysis are 































Table 2.1. List of probes used for RT-PCR
Antibody Dilution Company Clone/RRID  
Rabbit anti-PARP Ab 1:1000 Cell Signaling 46D11  
Goat anti-rabbit HRP-linked secondary Ab 1:2000 Cell Signaling 7074S  







Mouse anti-GAPDH Ab 
 
1:4000 Ambion 6C5 
 
 





Alexa Fluor 488 Goat anti-Rabbit IgG 1:1000 Invirogen AB_143165  
Rabbit polyclonal to Catalase 1:500 abcam ab16731 
 
 




Table 2.2. List of antibodies used for immunoblot and immunofluorescence staining 
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incubated with freshly prepared SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific, USA) for 1-5 min and imaged using luminescent image analyzer 
(Image Quant LAS 4000, GE Healthcare Life Sciences, PA, USA).  Densitometry 
analyses were performed using Image J software (National Institutes of Health, USA).  
Catalase activity assay  
Catalase activity present in liver homogenates was assessed in order to provide 
an approximation of the alteration to peroxisomal anti-oxidative function.  50 mg tissue 
homogenates were prepared and used for catalase activity assay using standard protocol 
of catalase activity colorimetric/fluorometric assay kit (BioVison Inc., USA). 
16S rRNA analyses 
To investigate the impact of change of diet on gut microbiota, diet-conversion 
experiment was performed.  In this experiment, six-week-old mice were fed milk diet (MD) 
for 16 weeks. Then, the diet was switched from MD to control diet (CD) for another 16 
weeks.  Following euthanization, mice abdomen was opened and stool pellets were 
collected from the severed distal ilium using blade and tweezers.  Collected stool was 
snap frozen and stored at -80°C.  Analysis of the 16S bacterial DNA from was carried out 
at the Microbiome Core Facility of the University of North Carolina. DNA was extracted 
from samples using the Epicentre® MasterPure Complete DNA Purification Kit (Illumina, 
Inc.) and bacterial DNA was amplified and sequenced by the Illumina MiSeq system. 16S 
rDNA amplicons was purified and quantified on an Invitrogen Qubit system and assessed 
on an Agilent Bioanalyzer.  Following quality filtering, sequences was de-multiplexed and 
trimmed using QIIME open source software (http://qiime.org).  Downstream alignment of 
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QIIME processed sequences; identification of open taxonomic units (OTUs), clustering, 
and phylogenetic analysis was conducted using the Phylosift open source software 
package (http://phylosift.wordpress.com).  Statistical analyses of community diversity 
within and amongst experimental groups included Principal Components Analysis, 
Squash Clustering, and Kantorovich-Rubinstein distance (akin to weighed UniFrac).  
Isolation of kupffer cells and flow cytometric analyses 
In order to do the flow cytometric analysis, kupffer cells were isolated from the liver 
using the following protocol [147, 148].  Livers were perfused with 5 ml Hank’s balanced 
salt solution (HBSS), followed by 12 ml digestion buffer (HBSS containing 0.5 mg/ml type 
VI collagenase (Sigma-Aldrich) and 10 mg/ml DNase I (Roche)).  The livers were 
removed, minced and incubated in digestion buffer at 37°C for 20 min with subsequent 
passage through a 40 mm cell strainer.  Parenchymal cells were removed by low speed 
centrifugation at 50xg for 2 min.  The supernatant enriched in non-parenchymal cells was 
centrifuged at 800xg for 30 min through a 25% (v/v) percoll gradient at room temperature 
with no brake.  The pellets of the gradient containing kupffer cells were washed and used 
for flow cytometric staining. 0.5–5 × 106 cells in 200 µl stain buffer plus Fc blocker (1:50) 
in FACS tubes were incubated on ice for 20 min.  Then, surface marker-specific 
conjugated antibodies or unconjugated primary antibodies (5 µl/106 cells) (Table 2.3) were 
added and incubated for 30 min on ice in the dark.  Then, cells were washed and 
incubated with conjugated secondary antibodies (5 µl/106 cells) for 30 min on ice in the 
dark.  After incubation, cells were again washed and treated with propidium Iodide at the 
concentration of 1 µg/ml.  Then, the cells were run through LSR II flow cytometer (BD, 







All values were expressed as mean ± standard error of the mean.  Statistical 
significance was chosen a priori as α ≤ 0.05.  Two groups of data were analyzed using 
non-parametric statistics employing the Mann-Whitney U test to analyze single, unpaired 
comparisons of normally distributed data sets.   Multiple groups of data were analyzed 
using nonparametric one way ANOVA. Statistical analyses were performed using 
GraphPad PRISM version 7.  
 
 
Antibodies Target cells Company Clone  
Ly6G BV650 Granulocytes, Neutrophil, 
Eosinophil 
BD Biosciences 1A8  
 
SiglecF BV650 Granulocytes, Neutrophil, 
Eosinophil 
BD Biosciences E50-2440 
 
Ly6C BV421 Monocytes BD Biosciences AL-21 
 
F4/80-Biotin Kupffer cells Biolegend BM8 
CD45.1 PECy7 Donor cells BD Biosciences A20 
 
CD45.2 PerCP-Cy5.5 Recipient cells BD Biosciences 104 
 
Streptavidin-QDot650 Kupffer cells ThermoFisher - 
Fc blocker Fc receptor blocker BD Biosciences 2.4G2   
 
Propidium iodide Dead cells ThermoFisher - 




Dietary Model of NASH: Pathology of NASH Develops at a Higher 





























In order to study NASH, it is essential to have an animal model that faithfully mimics 
the pathology and symptoms of the disease observed in humans.  Of the different NASH 
models available, those employing a high fat diet to facilitate the development of NASH 
better represent the symptoms and pathological indicators of NASH than those relying on 
genetic perturbation or other forms of dietary intervention.  Both unsaturated and 
saturated fats result in hepatic steatosis followed by the development of NASH.  However, 
their comparative role in triggering inflammation in the fatty liver is still unclear.  Reports 
state that saturated fatty acids are more toxic than unsaturated fatty acids.  Therefore, we 
hypothesized that mice fed a saturated high fat diet would manifest higher level of 
inflammation in the liver compared to mice fed an unsaturated high fat diet.  To test this 
hypothesis, 6-8 week-old mice were fed three distinct diets: a low fat control diet ((CD), 
10% calories from fat), a lard-based unsaturated high fat diet ((LD), 60% calories from 
unsaturated fat), and a milk-based saturated high fat diet ((MD), 60% calories from 
saturated fat).  The mice were fed for a period of 8, 16 or 32 weeks in order to assess the 
time at which NASH was clinically more apparent.  Serum and liver tissues were 
examined for inflammation-indicative markers, which demonstrated an elevated level of 
NASH in mice fed LD or MD compared to the mice fed CD at week 16 and 32.  At week 
8, none of the mice fed LD or MD developed significant level of NASH as compared to 
the mice fed CD.  As a comparison between LD and MD, mice fed MD exhibited a higher 
trend of NASH than the mice fed LD at week 16 and 32.  In conclusion, while both types 
of high fat diets can induce NASH in mice after 16 or 32 weeks of feeding, saturated high 




In order to develop a strategy for the successful management of NASH, we first 
need to understand the pathogenesis of the disease.  To this end, it is essential to be able 
to follow the progression of disease in human patients or experimental models [149].  
Although human patients are the first choice for studying NASH, it is subjected to some 
major limitations. Because of the long period of time, sometimes even decades, required 
to develop NASH in humans, and given the ethical restrictions of administering drugs to 
and collecting liver tissues from NASH patients, it is extremely important to have an 
experimental model faithfully mimicking NASH [150].  A suitable animal model of NASH 
can help researchers understand the pathology of NASH and test the effects of different 
therapeutic products [150, 151].  An appropriate animal model of NASH should correctly 
reflect the histological lesions (fat accumulation, immune infiltration, fibrosis) and 
pathophysiological indicators observed in human patients [151].  Currently both genetic 
and dietary models of NASH are available.  Because none of these models perfectly 
mimics the histopathology or pathophysiology of NASH in humans, they are only useful 
for investigating certain aspects of the disease.  Available genetic models of NASH are 
sterol regulatory element binding protein (SREBP)-1c transgenic mice, leptin deficient 
ob/ob mice, leptin receptor deficient db/db mice, phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) null mice, agouti gene mice, peroxisome proliferator-
activated receptor-α (PPAR-α) knockout mice, acyl-coenzyme A oxidase (AOX) null mice 
and methionine adenosyltransferase-1A (MAT-1A) null mice [53, 150, 151].  One major 
limitation of these genetic models of NASH is that none of the genetic perturbations are 
present in the human patients.  Moreover, some of these models (ob/ob mice, db/db mice 
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and agouti mice) do not progress from steatosis to steatohepatitis spontaneously.  They 
require an additional insult ( e.g. feeding with special diet) to induce steatohepatitis [150].  
As compared to the genetic models, dietary models have a higher relevance to NASH in 
humans, because they develop the disease only through the consumption of special diets 
without the need for genetic alterations. Currently available such special diets are 
methionine choline deficient diet, diet containing cholesterol and cholate, fructose 
enriched diet, and high fat diet [150, 151].  An important limitation of these dietary models 
is that none of these diets represents regular human diet.  A Combination of genetic 
perturbation and dietary challenge can also develop the histopathological and 
pathophysiological features of NASH [152-156].  Of these available genetic and dietary 
models, high fat diet-mediated NASH is clinically more relevant due to its similarity to the 
‘western diet’ in having high fat content.  
A typical ‘Western diet’ contains calories from both unsaturated and saturated fats 
[157].  A Pro-inflammatory role for saturated fats has been demonstrated in different 
diseases [158-163].  Diets containing high amount of saturated fats have been linked with 
coronary heart disease, insulin resistance, metabolic syndrome and diabetes [158].  
Saturated high fat diet causes higher incidence of colitis in genetically susceptible mice 
compared to the polyunsaturated high fat diet [159].  Role of saturated fats in the 
progression of NAFLD has also been shown in numerous reports [160-163].  Saturated 
fats mediate NAFLD through the accumulation of elevated level of reactive oxygen 
species, endoplasmic reticulum stress and lipotoxicity [164].  Due to these pro-
inflammatory roles of saturated fat over unsaturated fat, it was investigated in this study 
whether a milk-based saturated high fat diet (MD) is more efficient in inducing NASH 
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compared to the lard-based unsaturated high fat diet (LD).  It was reported that feeding 
of mice with high fat diet for 8-12 weeks could induce NASH [133, 142], but no previous 
study had demonstrated the impact of different feeding periods on NASH development.  
Therefore, an important aspect of this study was to identify an optimum time (8, 16 or 32 




















Both LD and MD led to the development of hepatic steatosis at week 16 and 32, 
while MD showed a non-significant higher trend than LD  
Both of the mice fed LD or MD led to the development of hepatic steatosis at week 
16 and 32 (Figure 3.1).  Representative images of H&E and ORO stained liver sections 
clearly displayed massive fat accumulation in the livers of mice fed LD or MD at week 16 
(Figure 3.1A).  Clinical scores of steatosis reflected higher levels of fat accumulation in 
the livers of mice fed LD or MD compared to the mice fed CD both at week 16 and 32 
(Figure 3.1B).  At week 8, there was only a higher trend of fat accumulation in the livers 
of mice LD or MD compared to the mice fed CD. When compared between LD and MD, 
mice fed MD showed higher trends of steatosis score compared to the mice fed LD at 
week 16 and 32.  
Both LD and MD led to the development of chronic inflammation in the fatty liver, 
while MD displayed a non-significant higher trend than LD at week 16 and 32 
Both of the mice fed LD or MD showed higher expression of TNF-α, IL-1β and 
CCL-2 , higher levels of NAFLD score, higher infiltration of neutrophils and macrophages, 
and elevated serum activities of ALT and AST compared to the mice fed CD at week 16 
and 32 (Figure 3.2A-H).  At week 8, both of the mice fed LD or MD showed only higher 
trend of NASH indicators compared to the mice fed CD.  When compared between LD 
and MD, mice fed MD showed higher trend of these NASH-indicative parameters 









Figure 3.1. Consumption of unsaturated or saturated high fat diet led to hepatic steatosis both at week 16 and 
32. Mice fed either a lard-based unsaturated or milk-based saturated high fat diet for 16 or 32 weeks responded with fat 
accumulation in their livers as shown by the representative images of (A) H&E and ORO stained liver sections (at 16 
weeks) and (B) clinical score of steatosis. CD, LD, and MD denote control diet, lard-based unsaturated and milk-based 
saturated high fat diet, respectively. # indicates significant difference between CD and LD when P<0.05, $ indicates 


























Figure 3.2. Feeding with unsaturated or saturated high fat diet led to the development of NASH both at week 
16 and 32. Mice fed either a lard-based unsaturated or milk-based saturated high fat diet for 16 or 32 weeks resulted 
in the development of NASH as indicated by the higher expression of (A) TNF-α, (B) IL-1β and (C) CCL-2, (D) 
higher levels of NAFLD score, higher infiltration of (E) neutrophil and (F) macrophages and higher serum activities 
of (G) ALT and (H) AST. CD, LD, and MD denote control diet, lard-based unsaturated and milk-based saturated 
high fat diet, respectively. # indicates significant difference between CD and LD when P<0.05, $ indicates significant 
difference between CD and MD when P<0.05, * indicates significant difference between LD and MD when P<0.05; 
data are expressed as mean±SEM; n=6-8 (Man-Whitney test). 
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Mice fed LD or MD both showed the indication of fibrosis in the fatty liver, yet 
feeding with MD showed a higher level of expression of TGF-β than feeding with 
LD 
Mice fed LD or MD both showed higher levels of indicators of fibrosis in their livers 
compared to the mice fed CD.  Representative images of picrosirius red stained liver 
sections of mice fed LD or MD at week 16 displayed higher levels of collagen 
accumulation compared to the mice fed CD (Figure 3.3A).  Mice fed LD or MD showed 
higher levels of expression Col-1a and TGF-β in their livers compared to the mice fed CD 
at week 16 and 32 (Figure 3.3B-C).  Mice fed MD showed significantly higher level of 






















Figure 3.3. Mice fed unsaturated or saturated high fat diet showed the indication of fibrosis both at week 16 
and 32. Mice fed either a lard-based unsaturated or milk-based saturated high fat diet for 16 or 32 weeks resulted in 
the accumulation of collagen in their livers as shown by the representative images of (A) picrosirius red stained liver 
sections (at 16 weeks) and higher levels of expression of (B) col-1a and (C) TGF-β. CD, LD, and MD denote control 
diet, lard-based unsaturated and milk-based saturated high fat diet, respectively. # indicates significant difference 
between CD and LD when P<0.05, $ indicates significant difference between CD and MD when P<0.05, * indicates 






To investigate the pathogenesis of NASH, it is essential to have a model 
appropriately mimicking the disease in human.  In compared to the genetic models, 
induction of NASH in obesogenic high fat diet-fed mice does not associate any genetic 
defects or pathological feature not observed in clinical paradigm of NASH [150, 165, 166].  
Therefore, a high fat diet model is considered as the clinically most relevant model of 
NASH.  Although high fat diets are widely used for NASH research, different pathological 
aspects of NASH in humans are poorly reflected in this model.  For instance, fibrosis is a 
very common phenomenon in patients with NASH.  Around 40% of NASH patients have 
advanced stages of fibrosis in their livers [167].  However, mice fed a high fat diet develop 
a very poor level of fibrosis, which is a major obstacle to study fibrosis in NASH using this 
model [168].  In the current study, mice fed a high fat diet for 16 or 32 weeks resulted in 
increased expression of col-1a and a pro-fibrotic cytokine TGF-β, and higher 
accumulation of collagen indicating an a progression to fibrosis.  Other indicators of 
NASH, e.g. higher expression of pro-inflammatory cytokines, immune infiltrations, and 
hepatocyte damage as reflected in higher serum ALT/AST level, were clearly manifested 
in mice fed either an unsaturated or saturated high fat diet.   
When compared the mice fed LD and MD, we detected a higher trend (although 
statistically non-significant) of NASH-indicative markers in mice fed MD compared to the 
mice fed LD at week 16.  Notably, differences between the mice fed LD and MD became 
less prominent at week 32.  This might be due to the maximum impacts of either types of 
diets on NASH, resulting in a level of saturation.  The higher level of inflammation in the 
livers of mice fed MD compared to the mice fed LD could be attributed to the higher 
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amount of saturated fatty acids in MD [164, 169].  Pro-inflammatory mechanisms of 
saturated fatty acids have been explained in different reports.  Excess free fatty acids, 
released from the lipolysis of subcutaneous and visceral adipose tissues, enter the liver.  
Upon entering the liver, free fatty acids are disposed through β-oxidation, triglyceride, and 
phospholipid synthesis.  Mitochondrial β-oxidation leads to the gradual break down of the 
fatty acids into two-carbon acetyl-coA which enters the tricarboxylic acid cycle.  Excess 
free fatty acids can also be disposed by esterification into triglycerides and phospholipids.  
In the case of excess level of saturated free fatty acids, higher amounts of saturated fatty 
acids are channeled to the esterification of phospholipids than to the esterification of 
triglycerides or β-oxidation.  Abnormal saturation of phospholipids can compromise the 
membrane fluidity of endoplasmic reticulum leading to impaired protein folding and 
trafficking which eventually results in endoplasmic reticulum stress through unfolded 
protein signaling pathway [164, 170-172].   
In compared to unsaturated fatty acids, saturated fatty acids are used for the 
synthesis of toxic molecules.  For instance, condensation of palmitate (16:0 saturated 
fatty acid) and serine leads to the synthesis of ceramide, a toxic lipid molecule [173, 174].  
Accumulation of ceramides in mitochondrial membrane results in an increased 
permeability resulting in cytochrome c release, that eventually induces apoptosis [175].  
Increased accumulation of ceramides in sphingolipid-rich lipid rafts of plasma membrane 
drives the coalescence of lipid rafts into larger platforms, which facilitate the apoptotic 
signaling by clustering membrane receptors and signaling molecules [176-179].  
Saturated fatty acid-derived ceramide can also directly interact with the pro-enzyme 
cathepsin D and induce its autolytic cleavage releasing the active components of 
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cathepsin D, which mediates the cleavage and activation of pro-apoptotic Bcl-2 family 
member Bid [180, 181].   
Another important difference between unsaturated and saturated fatty acids is that 
saturated fatty acids can induce inflammation through the direct interaction with, and 
activation of TLR-4 [182-184]. Saturated fatty acids are essential component of 
endotoxins. Human TLR-4 can sense only the endotoxins containing lipid-A portion 
accylated with six saturated fatty acids (usually 12-16 carbons in length).  It has been 
shown that replacement of these saturated fatty acids with monounsaturated or 
polyunsaturated fatty acids halts the pro-inflammatory effects of lipopolysaccharides [184, 
185].  From the inflammatory point of view, saturated fatty acids can also induce the 
expression of cyclooxygenase-2 through an NF-κB-dependent activation of macrophages 
[183]. Cyclooxygenase enzymes catalyze the synthesis of prostaglandins and 
thromboxanes, which are important mediators of different aspects of inflammation, e.g. 
vasodilation, leukocyte migration etc. [184, 186-188].  Therefore, it is possible that 
saturated fatty acids leads to the production of these mediators inducing pro-inflammatory 
immune infiltration in the fatty liver. 
Both LD and MD contain unsaturated and saturated fatty acids of different lengths 
and saturation types/levels, but the levels of saturated fatty acids, particularly the toxic 
ones like palmitic, stearic, and lauric acids, are higher in MD compared to LD [184, 189-
191]. Because of the higher pro-inflammatory roles of saturated fatty acids over 
unsaturated fatty acids, as reflected in the higher trends of NASH-indicative markers in 
mice fed MD versus the mice fed LD, we chose MD to induce NASH in mice for the 




High Fat Diet-mediated Nonalcoholic Steatohepatitis Impairs Hepatic 





























Although surgical resection of part of the liver (partial hepatectomy) is a well-
recognized treatment option for hepatocellular carcinoma, pre-existing pathological 
abnormalities originating from fat-rich diet mediated steatosis can alter the postoperative 
outcomes.  Despite the well-established effect of NASH in liver, little is known about the 
impact of fat-rich diet on the ability of the liver to regenerate. In this study, we investigated 
the impact of both saturated and unsaturated fat-rich diet on liver regeneration following 
partial hepatectomy in C57BL/6 mice.  Six week-old mice were fed control diet (CD), Lard-
based unsaturated fat-rich diet (LD) or milk-based saturated fat-rich diet (MD) for 16 
weeks.  Partial hepatectomy (70% of the liver) was carried out at 16 weeks.  At day 2 and 
at day 7 post partial hepatectomy, mice were injected with 5-bromo-2'-deoxyuridine 
(BrdU) i.p., one hour prior to euthanization to analyze hepatic regeneration.  Samples 
were collected from the resected and regenerated liver and examined for inflammation-
indicative markers and histological analyses.  Mice fed LD or MD exhibited higher 
nonalcoholic fatty liver disease (NAFLD) score, levels of inflammatory cytokines, and 
infiltration of neutrophil and macrophage in both resected and regenerated livers 
compared to mice fed CD. Mice fed LD or MD resulted in decreased BrdU incorporation 
in their resected and regenerated livers compared to the mice fed CD. Our study 
demonstrated the impaired hepatic regeneration post partial hepatectomy of mice fed LD 
or MD compared to that of mice fed CD.  Importantly, mice fed MD demonstrated reduced 
regeneration compared to the mice fed LD.  Collectively, this study illustrates the 





The liver has a unique ability to regenerate, even when mature, following a toxic 
insult or partial hepatectomy (PHx) [192, 193].  In spite of its substantial metabolic role, 
the liver is a quiescent organ in terms of hepatocyte proliferation.  Although hepatocytes 
undergo a very low rate of proliferation under normal conditions, they can reach a 
dramatically high proliferation rate within the acinar architecture of the remnant liver 
following a surgical resection leading to total recovery of the organ within 2-6 weeks [194].  
As a result of this ability to regenerate, surgical resection is often considered a viable 
treatment option for end stage liver diseases including liver cirrhosis or hepatocellular 
carcinoma [195, 196].  Although surgical resection of part of the liver (PHx) is considered 
a viable treatment option for patients with end-stage liver diseases, post-resection 
regeneration capacity is of major concern. Therefore, it is important to have a clear 
understanding of the effect that pre-existing steatosis or NASH have on the hepatic 
regeneration following PHx.  
Although the role of a high fat diet in causing an impairment of hepatic regeneration 
following PHx in mice has been reported [142], it is still not clear how differently NASH, 
induced by either unsaturated or saturated high fat diet, may impact hepatic regeneration 
following PHx.  This study assessed the ability of a lard-based unsaturated high fat diet 
(LD) and a milk-based, saturated fat rich diet (MD) in conferring an impairment to the 
livers of mice to regenerate following a PHx.  The findings here may influence the decision 






Mice fed LD or MD led to the development of NASH in both resected and 
regenerated livers 
Levels of expression of TNF-α, IL-1β, TGF-β, and CCL-2 were increased in both 
of the resected and regenerated livers of mice fed either LD or MD compared to the mice 
fed CD (Figure 4.1A-D).  Hepatic infiltrations of neutrophils and F4/80+ macrophages were 
increased in both of the resected and regenerated livers of mice fed either LD or MD 
compared to the mice fed CD (Figure 4.1E-F).  Each of these NASH indicators clearly 
demonstrated the development of NASH in the resected and regenerated livers of mice 
fed LD or MD.   Noticeably, resected and regenerated livers of mice fed the MD trended 
to exhibit higher levels of expression of inflammatory cytokines (Figure 4.1A-D) and 
infiltration of neutrophils and macrophages (Figure 4.1E-F) compared to the levels 
observed in mice fed the LD.   
Both LD and MD caused damage in resected and regenerated livers 
Both of the resected and regenerated liver sections from mice fed either LD or MD 
displayed higher NAFLD scores compared to the mice fed CD (Figure 4.2A).  Liver 
sections from the mice fed MD trended to have higher NAFLD scores compared to the 
mice fed LD (Figure 4.2A).   Sera from mice fed LD or MD showed increased levels of 
ALT (Figure 4.2B) and AST (Figure 4.2C) both on day-2 or day-7 compared to the mice 
fed CD. This indicated higher levels of liver damage in the mice fed unsaturated or 














Figure 4.1. Unsaturated or saturated high fat diet led to the development of NASH in both resected and 
regenerated livers.  Both of the lard-based unsaturated and milk-based saturated high fat diet resulted in the 
development of NASH as evidenced by increased expression of pro-inflammatory cytokines: (A) TNF-α, (B) IL-
1β, (C) TGF-β and (D) CCL-2; increased infiltration of (E) neutrophils and (F) macrophages. CD, LD, and MD 
denote control diet, lard-based unsaturated and milk-based saturated high fat diet, respectively. *P<0.05, 





























Figure 4.2. Unsaturated or saturated high fat diet resulted in liver damage in both resected and regenerated livers. 
Unsaturated or saturated high fat diet resulted in (A) higher NAFLD scores and elevated level of serum (B) ALT and (C) 
AST. (D) Western blot images demonstrated higher level of cleavage of poly ADP-ribose polymerase (PARP) in the livers 
of mice fed unsaturated or saturated high fat diet ( shown regenerated day-2) (E) Densitometry analyses of immunoblots 
exhibited increased level of cleavage of PARP in resected and regenerated livers of mice fed unsaturated or saturated high 
fat diet. CD, LD, and MD denote control diet, lard-based unsaturated and milk-based saturated high fat diet, respectively. 




the mice fed MD showed a higher trend of ALT and AST levels both on day-2 and day-7 
compared to the mice fed LD. 
Apoptosis resulting from the NASH-mediated hepatic tissue injury was determined 
by comparing the level of cleaved poly ADP-ribose polymerase (PARP).  Both resected 
and regenerated tissues on day-2 or day-7 from the mice fed MD showed an increased 
level of cleaved PARP compared to the mice fed CD (Figure 4.2D-E).  Mice fed LD 
showed an increased level of cleaved PARP in the tissues from the resected and 
regenerated day-2 livers compared to the mice fed CD (Figure 4.2E).  However, mice fed 
MD displayed a higher trend of PARP cleavage compared to the mice fed LD in both 
resected and regenerated livers on day-2 and day-7 (Figure 4.2E). 
NASH-affected livers of mice fed MD or LD demonstrated impaired regeneration 
following partial hepatectomy (PHx) 
Percentage of BrdU-incorporated hepatocytes was determined in regenerated liver 
sections on day-2 and day-7 in order to assess the effect of NASH on hepatic 
regeneration following partial hepatectomy.  The percentage of BrdU-incorporated 
hepatocytes was 2.2 and 5.2 fold lower in the regenerated liver sections of mice fed LD 
or MD respectively compared to that of the regenerated liver sections of mice fed CD on 
day-2 (Figure 4.3A).  These data demonstrate the impaired hepatic regeneration in mice 
fed fat-rich diet of either types compared to the mice fed control diet. Of note, percentage 
of BrdU-incorporated hepatocytes was 2.3-fold lower in mice fed MD compared to the 
mice fed LD.   This observation was consistent with the higher trending indicators of NASH 
(Figure 2.1), hepatic damage (Figure 4.2A-C) and apoptosis (Figure 4.3D-E) in the livers 
of the mice fed MD when compared to the livers of mice fed LD. Because hepatic 
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regeneration following PHx reached the level of saturation by day-7 [197], no significant 
difference in BrdU incorporation was observed at day-7.  However, the percentage of 
BrdU-incorporated hepatocutes trended to be lower in the livers of mice fed LD or MD 
compared to that incorporated into the livers of mice fed CD. 
Regenerated liver output was measured as the ratio of regenerated liver-to-total 
body weight (Figure 4.3B) or regenerated liver-to-resected liver weight (Figure 4.3C).  In 
either cases, ratios were lower in mice fed LD or MD compared to those of mice fed CD 
on day-7.   Regenerated livers from the mice fed LD or MD showed a 1.3 and 1.2-fold 
reductions to regenerated liver-to-body weight ratios, respectively compared to the mice 
fed CD (Figure 4.3B).   Regenerated livers from the mice fed LD or MD were found to 
have 1.7 and 1.6 fold reduction in their regenerated liver-to-resected liver weight ratio 
respectively compared to the mice fed control diet (Figure 4.3C).  These data again 


















Figure 4.3. Hepatic regeneration following partial hepatectomy was impaired in mice fed unsaturated or 
saturated high fat diet. NASH induced through the consumption of high fat diets resulted in impaired regeneration of 
partially resected livers as evidenced by (A) reduced rates of BrdU incorporation in hepatocytes, decreased (B) 
regenerated liver/body ratio and (C) regenerated liver/resected liver ratio. CD, LD, and MD denote control diet, lard-
based unsaturated and milk-based saturated high fat diet, respectively. *P<0.05, **P<0.01 (Man-Whitney test); data are 
expressed as mean±SEM; n=6-8.  
BrdU incorporation 




NASH is presently the third most common cause of end stage liver diseases necessitating 
transplantation.  If current trends continue, NASH is anticipated to surpass hepatitis C as 
the dominant cause of liver failure and will likely increase the rate of hepatocellular 
carcinoma (HCC) [23, 198].  Although liver transplantation has opened a new avenue for 
the treatment of HCC, the benefit of this treatment is limited mainly by shortage of 
available grafts and also long-term complications such as immunosuppression-related 
infections, risk of tumor progression etc.  Therefore, PHx is still considered as the most 
viable treatment for HCC [199].  Because of the co-existence of NASH and HCC in a large 
number of patients [200, 201], it is important to investigate how the presence of NASH 
would affect hepatic regeneration in these patients following PHx. Absence of an 
appropriate animal model that effectively mimics the genesis of human NASH represents 
a barrier in being able to appreciate the consequences that NASH has on hepatic 
regeneration following surgical resection.  However, amongst the currently available 
genetic and dietary models, dietary fat induced NASH is clinically more relevant. 
Previously, we have shown how employing a model requiring significant exposure to a 
fat-rich diet was sufficient to induce and then mimic the complex behavior associated with 
NASH that closely reflects what occurs in humans [163].  Our current data primarily 
demonstrates that long-standing hepatic steatosis in mice fed high fat diet leads to NASH 
and impairs hepatic regeneration following PHx.  Comparison between the impacts of 
unsaturated and saturated dietary fat on hepatic regeneration was an additional aspect 
of this study.  The data collected provided evidence for a trend towards higher levels of 
expression of pro-inflammatory cytokines, increases in NAFLD score, collagen 
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accumulation, serum ALT/AST levels and apoptosis in the livers of mice fed MD 
compared to the mice fed LD indicating an exacerbating role of a diet high in saturated 
fats in causing NASH.   An exacerbation of impairment of hepatic regeneration following 
PHx in the fatty livers of mice fed MD was consistent with a higher trend of hepatic 
inflammation and hepatocyte damage compared to the mice fed LD.  Such a higher trend 
of hepatic inflammation can be attributed to aggravated oxidative stress, lipotoxicity, and 
endoplasmic reticulum stress mediated by the saturated fat [164, 169].  In our study, 
concentration of serum endotoxin was found to trend higher in mice fed MD compared to 
the mice fed CD and LD (Chapter 5).  Therefore, chronic endotoxemia might also be 
plausible in offering an explanation for higher inflammation in mice fed MD.  Several 
NASH drugs are now under phase 3 clinical trials. Therefore, it would also be important 
to test if the treatment of mice with a drug that reverses NASH could improve hepatic 
regeneration post PHx.  Treatment with such drug that suppresses NASH could make the 































Apart from fat accumulation, additional pro-inflammatory insults to the steatotic 
liver play an important role in the modulation of NASH.  The role of gut microbiota has 
been reported in metabolic syndrome. As NAFLD is the hepatic manifestation of 
metabolic syndrome, it is important to investigate the role of gut microbiota in the 
progression of disease from the benign hepatic steatosis to the stage with chronic 
inflammation.  Therefore, this part of our study investigated whether gut microbiota has 
any influence on the development of NASH.  Three specific experiments were 
accomplished:  First, individual groups of specific pathogen free (SPF) mice and germ 
free (GF) mice were fed a control diet (CD) or a milk based, saturated high fat diet (MD) 
for 8, 16 or 32 weeks.  The resulting decrease in the levels of NASH-indicative markers 
in GF mice fed MD compared to the SPF mice fed MD indicated the role of gut microbiota 
in mediating NASH.  Second, it was tested if the diminishing of gut microbiota could 
reduce the level of inflammation in the fatty livers of mice fed MD.  In order to do that, 
individual groups of SPF mice fed CD or MD were treated with broad spectrum antibiotics 
through drinking water for 16 weeks.  Treatment of mice fed MD with broad spectrum 
antibiotics resulted in a reduced level of NASH-indicative markers in their livers indicating 
the role of gut microbiota in modulating the dietary fat-mediated NASH.  Third, 
conventionalization of GF mice fed MD by fecal transfer from SPF mice resulted in an 
increased level of inflammation. These three experiments clearly showed the generalized 
role of gut microbiota in causing NASH.  In addition, 16S rRNA analysis resulted in 
alteration of relative abundance of specific phyla in mice fed MD, indicating their plausible 




Gut microbiota that dwell in the gastrointestinal tract consists of 100 trillion 
bacterial cells that weigh 1-2 kg in mass and possess 100-fold more unique genes than 
human genome [114, 202].  Gut microbiota play a crucial role in maintaining the normal 
human physiology and nutrition [65, 203]. Changes in gut microbiota have been shown 
to be associated with different metabolic and physiological disorders [86, 89, 122, 202, 
204, 205].  The evidence supporting the contribution of gut-liver axis to the development 
of NASH has accumulated over the last twenty years [206]. NASH was first encountered 
as a complication of jejuno-ileal bypass surgery used for the treatment of morbid obesity 
[207, 208].  Furthermore, NASH was also reported in case of jejunal diverticulosis and 
intestinal bacterial overgrowth in human [209, 210].  Experimental evidence about the 
role of gut microbiota in mediating NASH in animal models is also growing.  Initial clues 
came from the studies of Backhead and colleagues [85, 88].  They showed that germ free 
(GF) mice fed high fat diet gained less weight compared to the specific pathogen free 
(SPF) mice fed high fat diet.  Conventionalization of GF mice through fecal transfer from 
SPF mice resulted in an increase in body fat content [88].  Other studies have shown that 
GF mice fed high fat diet are resistant to hepatic steatosis [211, 212].  One study reported 
that transfer of gut microbiota from steatotic mice to GF mice can promote the 
development of high fat diet-induced steatosis [211].  The  pathogenic role of intestinal 
bacteria in causing NASH was also supported by the observation that administration of 
antibiotics can improve NASH in rat and human [213].  All of these studies suggested the 
role of gut microbiota in the pathogenesis of NASH. Therefore, in this chapter, 
comprehensive experiments were designed to demonstrate an obvious involvement of 
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gut microbiota in mediating high fat diet-induced NASH using both GF and broad 
spectrum antibiotics-treated mice.  The role of gut microbiota in causing NASH was also 
investigated through the restoration of gut microbiota in GF mice fed milk-based high fat 
diet (MD).  Any change to the population composition of gut microbes in mice fed high fat 
diet may reveal a taxa-specific role of gut microbiota in mediating NASH.  Therefore, 16S 
rRNA analysis was performed to elucidate a plausible change in the composition of gut 

















GF mice developed less steatosis in their livers compared to the SPF mice 
After feeding with MD, GF mice showed less body weight and percent of body 
weight increase compared to the SPF mice at week 8, 16 and 32 (Fig. 5.1A-B).  GF mice 
fed MD showed reduced liver weight and liver-to-body weight ratio compared to the SPF 
mice fed MD at week 32 (Fig. 5.1C-D).  H&E staining of the liver sections (Fig. 5.1E) and 
clinical scores of steatosis (Fig. 5.1F) displayed a lower trend of fat accumulation in the 
livers of GF mice fed MD compared to the SPF mice fed MD at week 16 and 32.  These 
data indicate the role of gut microbiota in mediating hepatic steatosis.  
Steatotic livers in GF mice were resistant to NASH 
To investigate the development of inflammation in steatotic livers, levels of different 
NASH-indicative markers were analyzed. Expression levels of TNF-α, IL-1β, CCL-2 and 
TGF-β (Fig. 5.2A-D) and infiltration of neutrophils and macrophages (Fig. 5.2E-F) in the 
livers of GF mice fed MD failed to show any increase compared to the GF mice fed CD 
at any time point.  On the other hand, SPF mice fed MD showed significant increases of 
expression of TNF-α, IL-1β, CCL-2 and TGF-β (Fig. 5.2A-D) and infiltration of neutrophils 
and macrophages (Fig. 5.2E-F) compared to the GF mice fed MD at week 16 and 32.  
Although there was an increase of NAFLD score in GF mice fed MD compared to the GF 
mice fed CD at week 16 and 32 (Fig. 5.2G), it was significantly lower (approximately 1.3 
to 2-fold) than the SPF mice fed MD.  These data demonstrate that the steatotic livers in 
GF mice fed MD are protected from NASH, thus indicating the role of gut microbiota in 
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F Steatosis score 
Figure 5.1.  Germ free mice fed high fat diet developed less hepatic steatosis compared to the specific pathogen 
free mice.  Feeding with high fat diet resulted in less (A) body weight, (B) body weight change, (C) livers weight and (D) 
liver-to-body weight ratio in germ free mice compared to the specific pathogen free mice.  Less steatosis was observed 
in the livers of germ free mice fed high fat diet compared to the specific pathogen free mice fed high fat diet as shown by 
the (E) representative images of H&E stained liver sections (at 16 weeks) and (F) steatosis score. GF, SPF, CD and MD 
denote germ free mice, specific pathogen free mice, control diet and milk-based high fat diet, respectively.  *P<0.05, 
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G NAFLD score 
Figure 5.2.  Germ free mice fed high fat diet showed lower levels of NASH-indicative markers in their livers 
compared to the specific pathogen free mice fed high fat diet.  Germ mice fed high fat diet showed lower levels 
of (A-D) expression of TNF-α. IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, and (G) 
NAFLD score in their livers compared to the specific pathogen free mice fed high fat diet.  GF, SPF, CD and MD 
denote germ free mice, specific pathogen free mice, control diet and milk-based high fat diet, respectively.  *P<0.05, 
**P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8. 
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GF mice fed MD had decreased level of collagen accumulation in their livers 
compared to the SPF mice fed MD 
Collagen accumulation, a sign of hepatic fibrosis, is very common in chronic inflammation 
in fatty liver [140]. Therefore, the level of collagen accumulation was determined as a 
strong indicator of NASH. Reduced level of collagen accumulation was observed in 
picrosirius red-stained liver sections of GF mice fed MD compared to the SPF mice fed 
MD at week 16 and 32 (data shown at 16 week, Fig. 5.3A). Reduced level of collagen 
accumulation was reflected in the decreased expression of Col-1 and α-SMA, two 
important pro-fibrotic proteins [214, 215], in the livers of GF mice fed MD compared to the 
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Figure 5.3.  Germ free mice fed high fat diet showed decreased level of collagen accumulation in their livers 
compared to the specific pathogen free mice.  Feeding high fat diet resulted in decreased level of collagen 
accumulation in the livers of germ free mice compared to the specific pathogen free mice as shown by the (A) 
representative images of picrosirius red stained liver sections (at 16 weeks) and expression of (B) Col-1a and (C) α-
SMA. GF, SPF, CD and MD denote germ free mice, specific pathogen free mice, control diet and milk-based high fat 
diet, respectively.  *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8. 
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Broad spectrum antibiotics-treated mice fed MD showed similar levels of steatosis, 
but had a decreased level of NASH compared to the control mice fed MD 
The treatment of mice fed MD with broad spectrum antibiotics failed to make any 
difference in the level of steatosis in their livers compared to the control mice fed MD (Fig. 
5.4A).  Similar clinical scores of steatosis were observed in the livers of broad spectrum 
antibiotic-treated mice and control mice (Fig. 5.4B).  Although the treatment of mice fed 
MD with broad spectrum antibiotic did not result in any difference in the level of hepatic 
steatosis, it resulted in decreased levels of NASH-indicative markers in the livers of 
antibiotic-treated mice fed MD compared to the control mice fed MD (Fig. 5.5).  Broad 
spectrum antibiotic-treated mice fed MD showed decreased expression of TNF-α, IL-1β, 
CCL-2 and TGF-β, reduced infiltration of neutrophils and macrophages, and lower trends 
of serum activities of ALT and AST and NAFLD scores when compared to the control 
mice fed MD (Fig. 5.5A-I).  Decreased level of NASH in the livers of broad spectrum 
antibiotic-treated mice fed MD resulted in improved liver health as demonstrated by 
significantly higher liver-to-body weight ratio compared to the control mice fed MD (Fig. 
5.5J).  Picrosirius red stained liver sections demonstrated that broad spectrum antibiotic-
treated mice fed MD had decreased accumulation of collagen in their livers when 
compared to the control mice fed MD (Fig. 5.6A).  Broad spectrum antibiotic-treated mice 
fed MD showed a lower trend of expression of pro-fibrotic Col-1 and α-SMA in their livers, 
(Fig. 5.6A) which corroborates the reduced accumulation of collagen. Collectively,  
decreased levels of NASH-indicative and pro-fibrotic markers in the livers of broad 
spectrum antibiotic-treated mice fed MD, when compared to the control mice fed MD, 











Figure 5.4.  Broad spectrum antibiotic-treated mice fed high fat diet developed similar level of hepatic 
steatosis compared to the control mice.  Feeding with high fat diet resulted in similar steatosis in the livers of broad 
spectrum antibiotic-treated mice compared to the control mice as shown by the (A) representative images of H&E 
stained liver sections and (B) steatosis score.  CD and MD denote control diet and milk-based high fat diet, 










































Figure 5.5.  Broad spectrum antibiotic-treated mice fed high fat diet showed decreased levels 
of NASH-indicative markers compared to the control mice fed high fat diet.  Broad spectrum 
antibiotic-treated mice fed high fat diet showed lower levels of (A-D) expression of TNF-α, IL-1β, CCL-
2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum activities of ALT and AST, 
and (I) NAFLD scores in their livers compared to the control mice fed high fat diet.  (J) Decreased level 
of NASH resulted in better liver health as demonstrated by higher liver-to-body weight ratio in broad 
spectrum antibiotic-treated mice fed MD compared to the control mice fed MD.  CD and MD denote 
control diet and milk-based high fat diet, respectively.  *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney 
test); data are expressed as mean±SEM; n=6-8.  
G H 








B C Col-1 α-SMA 
Figure 5.6.  Broad spectrum antibiotic-treated mice fed high fat diet showed decreased level of collagen 
accumulation in their livers compared to the control mice fed high fat diet.  Broad spectrum antibiotic-
treated mice fed high fat diet displayed a lower trend of collagen accumulation in their livers compared to the 
control mice fed high fat diet as shown by the (A) representative images of picrosirius red stained liver sections 
and expression of (B-C) Col-1a and α-SMA.  CD and MD denote control diet and milk-based high fat diet, 
respectively.  (Man-Whitney test); data are expressed as mean±SEM; n=6-8. 
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Conventionalization of GF mice fed MD resulted in increased level of NASH  
To gain further evidence for the role of gut microbiota in mediating NASH, GF mice 
fed MD were conventionalized through the re-constitution of gut microbiota by fecal 
transplantation from SPF mice fed MD.  Re-constitution of gut microbiota in GF mice fed 
MD did not result in any difference in the level of steatosis in their livers as compared to 
the GF mice fed MD.  H&E staining of liver sections and their clinical scores for steatosis 
displayed a level of steatosis in the livers of gut microbiota re-constituted mice fed MD, 
that was similar to the steatosis observed in the livers of GF and control SPF mice fed 
MD (Fig. 5.7A-B).  Although the level of steatosis remained unchanged, the levels of 
different NASH-indicative markers significantly increased in the livers of gut microbiota 
re-constituted mice when compared to the GF mice (Fig. 5.8A-G).  Expression of TNF-α, 
IL-1β, CCL-2 and TGF-β (Fig. 5.8A-D) and infiltration of neutrophils and macrophages 
(Fig. 5.8E-F) were increased in the livers of gut microbiota reconstituted mice fed MD as 
compared to the GF mice fed MD.  Increased levels of these inflammatory markers 
resulted in a higher trend of NAFLD score in gut microbiota re-constituted mice as 
compared to the GF mice (Fig. 5.8G).  Re-constitution of gut microbiota in GF free mice 
fed MD also resulted in an increased accumulation of collagen as demonstrated by 
picrosirius red staining of liver sections (Fig. 5.9A).  This increase in collagen 
accumulation was also reflected in increased expression of Col-1 and α-SMA in the livers 
of gut microbiota re-constituted mice fed MD compared to the GF mice fed MD (Fig. 5.9B-
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Figure 5.7.  Reconstitution of gut microbiota in germ free mice fed high fat diet did not make any 
difference in the hepatic steatosis.  Feeding with high fat diet resulted in similar steatosis in the livers of 
conventionalized (gut microbiota re-constituted) mice compared to the germ free mice as shown by the (A) 
representative images of H&E stained liver sections and (B) steatosis score.  GF, GMR, SPF and MD denote 
germ free mice, gut microbiota re-constituted mice, specific pathogen free mice and milk-based high fat diet, 
















































Figure 5.8.  Reconstitution of gut microbiota in germ free mice fed high fat diet showed elevated levels of 
NASH-indicative markers in their steatotic livers.  Reconstitution of gut microbiota in germ free mice fed high fat 
diet resulted in increased levels of (A-D) expression of TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils 
and macrophages, and (G) NAFLD scores in their livers compared to the germ free mice.  GF, GMR, SPF and MD 
denote germ free mice, gut microbiota re-constituted mice, specific pathogen free mice and milk-based high fat diet, 
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Figure 5.9.   Reconstitution of gut microbiota in germ free mice fed high fat diet resulted in increased 
collagen accumulation in their steatotic livers.   Reconstitution of gut microbiota in germ free mice fed high fat 
diet displayed an increase in collagen accumulation in their livers compared to the germ free mice fed high fat diet 
as shown by the (A) representative images of picrosirius red stained liver sections and expression of (B-C) Col-1a 
and α-SMA.   GF, GMR, SPF and MD denote germ free mice, gut microbiota re-constituted mice, specific pathogen 




Composition of gut microbial community was altered in mice fed MD 
To determine whether a high fat diet could bring about a change in the structure of 
gut microbial community, which might better explain the observed role of gut microbiota 
in mediating NASH in the livers of mice fed MD, the composition of cecal microbiota was 
determined at phylum level using 16s rRNA analysis.  Indeed, the composition of gut 
microbial community was changed in mice fed MD.  Stacked bar diagram of gut microbial 
community revealed a shift in phylum level in mice fed MD as compared to the mice fed 
CD (Fig. 5.10A).  Structure of gut microbial community in mice fed MD became similar to 
mice fed CD when the diet was switched from MD to CD.  Relative abundances of 
Bacteroidetes, Actinobacteria, and Tenericutes were significantly decreased in mice fed 
MD as compared to the mice fed CD.  On the other hand, relative abundances of 
Proteobacteria, Verrucobacteria, and Firmicutes were significantly increased in mice fed 
MD as compared to the mice fed CD (Fig. 5.10B-G).  When the diet was switched from 
MD to CD, relative abundances of these six gut microbial phyla became similar to the 
mice fed CD.  Within the phylum Firmicutes, relative abundance of genus Clostridium 
trended to be higher in mice fed MD which became similar to the mice fed CD upon the 
change of diet from MD to CD (Fig. 5.10H).  Principal component analysis was performed 
based on the composition of gut microbiota in order to assess whether the mice fed MD 
were clustered differently than the mice fed CD.  Likewise, as we anticipated mice fed MD 
clustered differently versus the mice fed CD (Fig. 5.11A-B).  However, mice fed MD 
clustered similarly to the mice fed CD when the diet was changed from MD to CD, 
demonstrating that the composition of gut microbial community differs in mice fed MD 
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Figure 5.10.  Composition of gut microbiota changed in mice fed high fat diet.  Feeding of mice with high fat diet for 
16 weeks resulted in alteration of composition of gut microbial community which became similar to that of mice fed control 
diet upon the switch of diet from control diet to high fat diet as represented by (A) stacked bar diagram at phylum level and 
changes in relative abundances of (B) Bacteroidetes, (C) Proteobacteria, (D) Verrucobacteria, (E) Firmicutes, (F) 
Actinobacteria, (G) Tenericutes, and (H) Clostridium.  CD, MD and MD>CD denote control diet, milk-based high fat diet and 










Figure 5.11.  Principal component analysis resulted in different clustering of mice fed high fat diet. 
Principal component analysis based on the relative abundances of gut microbes at phylum level resulted in 
different clustering of mice fed high fat diet than mice fed control diet.  When the diet was switched from high 
fat diet to control diet, mice fed high fat diet clustered similar to the mice fed control diet.  CD, MD and MD>CD 
denote control diet, milk-based high fat diet and switched diet, respectively. Dark-filled dots, pink-filled dots 




In order to demonstrate the association of gut microbiota in transferring a steatotic   
liver to one with NASH, three specific experiments were conducted in this study.  First 
experiment was performed using GF mice which showed that GF mice fed MD are 
protected from NASH.  Second experiment was performed by the treatment of SPF mice 
fed MD with broad spectrum antibiotics.  Diminishing of gut microbiota through the 
treatment with broad spectrum antibiotics resulted in decreased levels of NASH-indicative 
markers in SPF mice fed MD.  Data from the experiment with broad spectrum antibiotics 
treatment was in line with the findings of GF mice experiment. Finally, in 
conventionalization experiment, gut microbiota was reconstituted in GF mice fed MD 
through fecal transfer from SPF mice fed MD, which resulted in increased levels of NASH-
indicative markers.   
Although the level of chronic inflammation in steatotic liver was decreased in both 
GF and broad spectrum antibiotics-treated mice as compared to the control mice, GF 
mice demonstrated better protection than broad spectrum antibiotics-treated mice.  
Whereas the GF mice fed MD were completely protected from elevated expression of 
pro-inflammatory cytokines and increased infiltration of innate immune cells, broad 
spectrum antibiotics-treated mice fed MD showed only a partial decrease in these NASH-
indicative markers, perhaps because gut microbes are not completely eliminated  through 
broad spectrum antibiotic treatment [216], while GF mice are free from all microbes.  
Therefore, it is possible that pro-inflammatory components coming from the remaining gut 
microbes of broad spectrum antibiotics-treated mice still have some causative effect on 
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the mediation of NASH.  At the same time, plausible direct therapeutic effect of antibiotics 
on the pathogenesis of NASH cannot be ruled out.   
Although the re-constitution of gut microbiota in GF mice fed MD resulted in an 
increase in the level of immune infiltration in their livers, it did not reach the level of 
immune infiltration in the livers of control SPF mice fed MD.  Perhaps, that occurred due 
to the fact  that gut microbiota-derived metabolites (e.g. short chain fatty acids) play an 
important role in the differentiation of embryonic immune progenitor cells, particularly the 
macrophage progenitor cells [217].  A defective prenatal differentiation of these immune 
progenitor cells may occur in the liver of GF mice due to the deficiency of gut microbiota-
derived metabolites.  Immune cells derived from this progenitor cells are called sessile 
cells.  It is possible that a portion of the sessile immune cells is deficient in the liver of GF 
mice due to the lack of gut microbiota-derived factors.  Postnatal re-constitution of gut 
microbiota in GF mice through fecal transplantation could only facilitate the differentiation 
of bone marrow-derived innate cells in the liver, but not compensate the missing sessile 
cells [218].  Therefore, the level of immune cell count in the liver of conventionalized GF 
mice never reached the level in SPF mice. 
Data from 16s rRNA analysis, as displayed by stacked bar diagram and principal 
component analysis, demonstrated a change in the composition of gut microbiota in mice 
fed MD as compared to the mice fed CD.  Although the relative abundance of 
Bacteroidetes, the major Gram negative phylum in the gut microbiota of mice, decreased, 
the relative abundance of two different Gram negative phyla, Proteobacteria and 
Verrucobacteria, significantly increased in the mice fed MD [219].  The important change 
in the relative abundance of Gram negative bacteria is mainly due to their contribution in 
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producing endotoxin.  It is still unclear how much of a role Proteobacteria or 
Verrucobacteria plays in maintaining the level of circulating endotoxin.  Apart from the 
alteration of gut microbial composition in the phylum level, we also observed a change in 
genus Clostridium in mice fed MD. Clostridium produces ethanol which, importantly, 
contributes to oxidative stress in the liver leading to NASH [220]. It requires further 
investigation to identify specific microbes potentially associated with the production of 
pro-inflammatory molecules or metabolites associated with NASH. In that case, 
application of microbe-specific antibiotics other than broad spectrum antibiotics may 















Role of Gut Microbiota in Causing NASH is Dependent on LPS-TLR-4-




















Increased level of LPS has been reported both in obese patients and experimental 
models of obesity.  It has also been reported that chronic administration of LPS in mice 
results in increased adipose tissue and body weight in a TLR-4 pathway-dependent 
manner.  In the previous chapter, we demonstrated the obvious role of gut microbiota in 
causing NASH.  LPS is known as a major gut-derived pro-inflammatory component in the 
liver.  Therefore, it demands a comprehensive study to investigate the potential role of 
LPS-TLR-4 pathway in the modulation of NASH by gut microbiota. Treatment of mice fed 
MD with broad spectrum antibiotics resulted in decreased concentration of serum LPS 
and indicators of NASH. Chronic injection of low dose LPS restored the higher level of 
serum LPS in mice fed MD.  The level of NASH was also increased upon injection of LPS 
corroborating the role of LPS in causing NASH. Simultaneous injection of TAK-242, a 
TLR-4 inhibitor, protected the mice fed MD from NASH demonstrating the role of LPS-
TLR-4 pathway in causing the disease.  It was also observed that TLR-4 KO mice fed MD 
had deceased level of NASH.  Chronic injection of LPS in TLR-4 KO mice fed MD failed 
to increase the level of NASH.  This observation further confirmed the involvement of 
LPS-TLR-4 pathway in causing NASH.  Because kupffer cells are the principal member 
of TLR-4-expressing community in the liver, we also attempted to investigate the role of 
kupffer cells in mediating NASH.  It was found that reconstitution of TLR-4 KO kupffer 
cells in the livers of wild-type mice fed MD by bone marrow transplantation resulted in a 
decreased level of NASH.  Conversely, reconstitution of wild-type kupffer cells in the livers 
of TLR-4 KO mice fed MD resulted in an increased level of NASH.  This experiment clearly 




Once the involvement of gut microbiota in causing NASH is demonstrated, the next 
question to resolve is the mechanism how gut microbiota contributes to NASH 
modulation.  One potential mechanism might be the engagement of TLRs and their gut 
microbiota-derived ligands known as microbe-associated molecular patterns.  LPS is a 
major microbe-associated molecular pattern drained into the portal circulation from 
intestine.  The concentration of LPS has been shown to be increased in obese patients 
as well as animal models of obesity [122, 123, 221, 222]. Role of LPS-TLR-4 pathway in 
metabolic syndrome was first studied by Cani et al. They showed that chronic 
endotoxemia created through the infusion of LPS using a subcutaneously implanted 
osmotic mini-pump had resulted in an increased body weight and adipose tissue in mice 
[122]. In the same report, they also showed that interruption of TLR-4 pathway through 
the knockout of CD14 prevents the LPS-infused mice from gaining increased body weight 
and adipose tissue.  These data demonstrated the role of LPS-TLR-4 pathway in obesity. 
In a follow-up report, Cani et al. showed that treatment of mice fed high fat diet with broad 
spectrum antibiotics had resulted in a reduced concentration of serum LPS and 
decreased body weight and adipose tissue, when compared to the control mice fed a high 
fat diet. This result demonstrated that gut microbiota plays a role in controlling obesity 
through metabolic endotoxemia.  Due to the close association of obesity and NAFLD, a 
similar role for the LPS-TLR-4 pathway is postulated in the pathogenesis of NASH.  
Therefore, the current study was designed to investigate the role of a gut-derived low 
grade chronic endotoxemia in causing NASH in mice fed high fat diet in a TLR-4 pathway-




Diminishing of gut microbiota resulted in reduced concentration of serum 
endotoxin which was restored upon LPS injection 
Diminishing of gut microbiota through the treatment of mice fed CD or MD with 
broad spectrum antibiotics resulted in reduced concentration of endotoxin in portal serum 
and feces (Fig. 6.1A-B).  This indicates that the concentration of serum endotoxin is 
dependent on the normal abundance of gut microbiota.  Injection i.p. of low dose LPS for 
four weeks led to the increase of concentration of endotoxin in portal serum (Fig. 6.1A).  
LPS injection resulted in increased level of NASH in broad spectrum antibiotics-
treated mice that were fed MD 
As discussed in the last chapter, treatment of mice fed MD with broad spectrum 
antibiotics resulted in decreased level of NASH.  This improvement of disease might be 
due to the reduced concentration of gut-derived endotoxin in the circulation of broad 
spectrum antibiotics-treated mice.  This assumption led us to test if the restoration of an 
increased level of serum endotoxin through the injection i.p. of a subclinical dose of 
exogenous LPS in broad spectrum antibiotics-treated mice could increase the severity of 
NASH.  LPS injection in broad spectrum antibiotics-treated mice fed MD, however, did 
not make any difference in fat accumulation and steatosis score (Fig. 6.2A and Fig. 6.2B), 
but that LPS injection did result in increased levels of expression of TNF-α, IL-1β, CCL-1 
and TGF-β, infiltration of neutrophils and macrophages, serum activities of ALT and AST 
and clinical scores of NAFLD as compared to the non-LPS injected/antibiotics-treated 












Figure 6.1. Diminishing of gut microbiota resulted in reduced concentration of endotoxin in portal serum 
and feces. Treatment of mice fed CD or MD with broad spectrum antibiotics resulted in reduced concentration 
of endotoxin in (A) portal serum and (B) feces. (A) Intraperitoneal injection of low dose LPS restored the serum 
endotoxin level in mice fed MD. CD and MD denote control diet and milk-based high fat diet, respectively. 
***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8. 
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were reflected in exacerbated liver health as shown by the reduced liver-to-body weight 
ratios of LPS-injected/antibiotics-treated mice fed MD, when compared to the only 
antibiotics-treated mice fed MD (Fig. 6.3J).  
LPS injection also resulted in increased collagen accumulation in the fatty livers of 
broad spectrum antibiotics-treated mice fed MD compared to the only antibiotics-treated 
mice fed MD, as demonstrated by elevated levels of picrosirius red staining of collagen 
and expression of col-1 and α-SMA (Fig. 6.4A-C).  These data demonstrated the role of 
the low concentration of gut-derived endotoxin in mediating NASH in the fatty liver.   
Administration of TLR-4 inhibitor (TAK-242) blunted the effect of injection of low 
dose LPS resulting in decreased level of NASH 
Administration of TAK-242 in antibiotics-treated/LPS-injected mice fed MD did not 
make any significant decrease in fat accumulation or steatosis score (Fig. 6.2A and Fig. 
6.2B), but resulted in reduced levels of expression of TNF-α, IL-1β, CCL-1 and TGF-β, 
infiltration of neutrophils and macrophages, serum activities of ALT and AST and clinical 
scores of NAFLD compared to the only antibiotics-treated/LPS-injected mice fed MD (Fig. 
6.3A-I).  Reduced level of NASH was consistent with the improved liver health as shown 
by the increased liver-to-body weight ratios in antibiotics-treated/LPS-injected/TAK-242-
administered mice fed MD, as compared to the only antibiotics-treated/LPS-injected mice 
fed MD (Fig. 6.3J).  
Administration of TAK-242 also resulted in reduced collagen accumulation in the 









Figure 6.2. Injection of LPS or TLR-4 inhibitor in broad spectrum antibiotics-treated mice fed high fat 
diet did not make alter hepatic steatosis. Intraperitoneal injection of low dose LPS or TLR-4 inhibitor (TAK-
242) in mice fed CD or MD did not alter hepatic steatosis as shown by (A) representative images of H&E 
stained liver sections and (B) steatosis score. CD and MD denote control diet and milk-based high fat diet, 
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Figure 6.3. Injection of low dose LPS in broad spectrum antibiotics-treated mice fed high fat diet resulted 
in increased level of NASH which was reversed upon administration of TLR-4 inhibitor. Injection of low 
dose LPS in broad spectrum antibiotics-treated mice fed MD resulted in increased levels of (A-D) expression of 
TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum activities of ALT 
and AST, and (I) NAFLD scores in their livers which was reversed upon administration of TLR-4 inhibitor (TAK-
242). (J) Increased level of NASH in LPS-injected/antibiotics-treated mice fed MD resulted in exacerbated liver 
health as demonstrated by reduced liver-to-body weight ratio which was reversed upon administration of TAK-
242. CD and MD denote control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001 
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Figure 6.4. Injection of low dose LPS in broad spectrum antibiotics-treated mice fed high fat diet resulted in 
increased accumulation of collagen which was reversed upon administration of TLR-4 inhibitor. Injection of 
low dose LPS in broad spectrum antibiotics-treated mice fed MD displayed an increased level of collagen accumulation 
in their livers which was reversed upon administration of TLR-4 inhibitor (TAK-242) as shown by the (A) representative 
images of picrosirius red stained liver sections and expression of (B-C) Col-1a and α-SMA. CD and MD denote control 




the antibiotics-treated/LPS-injected mice fed MD, as demonstrated by reduced levels of 
picrosirius red staining of collagen and expression of col-1 and α-SMA (Fig. 6.4A-C).  
These results demonstrate that circulating LPS induces inflammation in the fatty liver 
through the interaction with TLR-4 indicating an important role of LPS-TLR-4 axis in 
causing NASH.  
TLR-4 has an obvious role in the modulation of NASH in mice fed MD 
Livers from TLR-4 KO mice fed MD did not show any difference in fat accumulation 
or steatosis score as compared to the wild-type mice fed MD (Fig. 6.7A-B).  Likewise, 
injection of low dose LPS in TLR-4 KO mice fed MD did not cause any difference in fat 
accumulation or steatosis score as compared to the wild-type or TLR-4 KO mice fed MD 
(Fig. 6.7A-B).  These data indicate that TLR-4 does not have a clear role in fat deposition 
in the liver. 
Although TLR-4 did not show any role in fat accumulation in the livers of mice fed 
MD, yet it showed important role in the transitioning of fatty livers to chronic inflammatory 
stage.  TLR-4 KO mice fed MD exhibited reduced levels of expression of TNF-α, IL-1β, 
CCL-1 and TGF-β, infiltration of neutrophils and macrophages, serum activities of ALT 
and AST and clinical scores of NAFLD, as compared to the wild-type mice fed MD (Fig. 
6.8A-I).  Injection of low dose LPS in TLR-4 KO mice did not result in any increase in the 
levels of NASH-indicative markers as compared to the Only TLR-4 KO mice fed MD.  The 
reduced level of NASH was consistent with the improved liver health, as shown by the 
increased liver-to-body weight ratios in TLR-4 KO mice fed MD, when compared to the 









Figure 6.7. TLR-4 KO mice fed high fat diet displayed similar level of hepatic steatosis as compared to the 
wild-type mice fed high fat diet. TLR-4 KO and wild-type mice fed MD did not display any difference in hepatic 
steatosis as shown by the (A) representative images of H&E stained liver sections and (B) steatosis score. 
Intraperitoneal injection of low dose LPS in TLR-4 KO mice fed MD did not make any difference in hepatic steatosis 
as compared to the wild-type or TLR-4 KO mice fed MD. CD and MD denote control diet and milk-based high fat diet, 
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Figure 6.8. TLR-4 KO mice fed high fat diet exhibited decreased level of NASH which remained unchanged 
upon injection of low dose LPS. TLR-4 KO mice fed MD showed decreased levels of (A-D) expression of TNF-
α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum activities of ALT and 
AST, and (I) NAFLD scores in their livers as compared to the wild-type mice fed MD which remained unchanged 
upon low dose LPS injection. (J) Decreased level of NASH in TLR-4 KO mice fed MD resulted in improved liver 
health as demonstrated by increased liver-to-body weight ratio which remained unchanged upon low dose LPS 
injection. CD and MD denote control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001 




did not result in any significant difference in the levels of NASH-indicative markers as 
compared to the TLR-4 KO mice fed MD with no LPS injection.  
TLR-4 KO mice fed MD exhibited reduced collagen accumulation in their fatty livers 
as compared to the wild-type mice fed MD as demonstrated by reduced levels of 
picrosirius red staining of collagen and expression of col-1 and α-SMA (Fig. 6.9A-C).  
Injection of low dose LPS in TLR-4 KO mice fed MD did not make any increase in collagen 
accumulation in their livers as compared to the TLR-4 KO mice fed MD with no LPS 
injection.  These data demonstrate the role of TLR-4 in mediating NASH in mice fed MD. 
TLR-4-expressing kupffer cells play a crucial role in mediating NASH in mice fed 
MD 
Once the role of LPS-TLR-4 axis in causing NASH is demonstrated, the next 
question naturally rises is the role of kupffer cells, as they are the major TLR-4-expressing 
cells in the liver.  To address this question, wild-type mice fed CD or MD were 
reconstituted with TLR-4 KO kupffer cells, and TLR-4 KO mice fed CD or MD were 
reconstituted with wild-type kupffer cells through bone marrow transplantation.  It was 
observed that the reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice 
fed MD by bone marrow transplantation resulted in a decreasing trend of fat accumulation 
and steatosis score, as compared to the TLR-4+ kupffer cells-containing wild-type mice 
fed MD.  On the other hand, reconstitution of wild-type kupffer cells in the livers of TLR-4 
KO mice fed MD resulted in an increasing trend of fat accumulation and steatosis score, 
as compared to the TLR-4 KO kupffer cells-containing TLR-4 KO mice fed MD (Fig. 
6.10A-B).  These data indicate that TLR-4-expressing kupffer cells are involved in the 
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Figure 6.9. TLR-4 KO mice fed high fat diet displayed decreased level of collagen accumulation in their livers 
which remained unchanged upon injection of low dose LPS. TLR-4 KO mice fed MD showed decreased level of 
collagen accumulation in their livers as compared to the wild-type mice fed MD which remained unchanged upon 
injection of low dose LPS as shown by the (A) representative images of picrosirius red stained liver sections and 
expression of (B-C) Col-1a and α-SMA. CD and MD denote control diet and milk-based high fat diet, respectively. 








Figure 6.10. TLR-4-expressing kupffer cells are involved in the accumulation of fat in mice fed high fat diet. 
Reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice fed MD resulted in a decreasing trend of hepatic 
steatosis as compared to the TLR-4+ kupffer cells-containing wild-type mice fed MD; also, reconstitution of wild-type 
kupffer cells in the livers of TLR-4 KO mice fed MD resulted in an increasing trend of hepatic steatosis as compared to 
the TLR-4 KO kupffer cells-containing TLR-4 KO mice fed MD as shown by the (A) representative images of H&E 
stained liver sections and (B) steatosis score. CD and MD denote control diet and milk-based high fat diet, respectively. 
Data are expressed as mean±SEM; n=6-8. 
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Regarding the inflammation in the fatty liver, reconstitution of TLR-4 KO kupffer 
cells in the livers of wild-type mice fed MD by bone marrow transplantation resulted in 
reduced levels of expression of TNF-α, IL-1β, CCL-1 and TGF-β, infiltration of neutrophils 
and macrophages, serum activities of ALT and AST and clinical scores of NAFLD, when 
compared to the TLR-4+ kupffer cells-containing wild-type mice fed MD.  In the same time, 
reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD resulted in 
increased levels of expression of TNF-α, IL-1β, CCL-1 and TGF-β, infiltration of 
neutrophils and macrophages, serum activities of ALT and AST and clinical scores of 
NAFLD, when compared to the TLR-4 KO kupffer cells-containing TLR-4 KO mice fed 
MD. (Fig. 6.11A-I).  Decreased level of NASH in the livers of wild-type mice fed MD 
reconstituted with TLR4-KO kupffer cells was reflected in improved liver health, as 
demonstrated by the increased liver-to-body weight ratios.  Increased level of NASH in 
the livers of TLR-4 KO mice fed MD reconstituted with wild-type kupffer cells was reflected 
in exacerbated liver health, as shown by the decreased liver-to-body weight ratios (Fig. 
6.11J).  
Wild-type mice fed MD reconstituted with TLR4-KO kupffer cells exhibited reduced 
collagen accumulation in their livers, when compared to the wild-type mice fed MD 
containing TLR-4+ kupffer cells, as demonstrated by reduced levels of picrosirius red 
staining of collagen and expression of col-1 and α-SMA (Fig. 6.12A-C).  On the other 
hand, reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD 
resulted in increased collagen accumulation in their livers, when compared to the TLR-4 
KO mice fed MD containing TLR-4 KO kupffer cells, as shown by increased levels of 
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Figure 6.11. TLR-4-expressing kupffer cells play crucial role in mediating NASH in mice fed high fat diet. 
Reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice fed MD resulted in decreased levels of (A-
D) expression of TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum 
activities of ALT and AST, and (I) NAFLD scores as compared to the TLR-4+ kupffer cells-containing wild-type 
mice fed MD. (J) Decreased level of NASH in wild-type mice fed MD reconstituted with TLR-4 KO kupffer cells 
resulted in improved liver health as demonstrated by increased liver-to-body weight ratios. On the other hand, 
Reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD resulted in increased levels of (A-
D) expression of TNF-α, IL-1β, CCL-2 and TGF-β, (E-F) infiltration of neutrophils and macrophages, (G-H) serum 
activities of ALT and AST, and (I) NAFLD scores as compared to the TLR-4 KO kupffer cells-containing TLR-4 
KO mice fed MD. (J) Increased level of NASH in TLR-4 KO mice fed MD reconstituted with wild-type kupffer cells 
resulted in exacerbated liver health as demonstrated by decreased liver-to-body weight ratios. CD and MD denote 
control diet and milk-based high fat diet, respectively. *P<0.05, **P<0.01, ***P<0.001 (Man-Whitney test); data 
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Figure 6.12. TLR-4-expressing kupffer cells play an important role in collagen accumulation in the livers of 
mice fed high fat diet. Reconstitution of TLR-4 KO kupffer cells in the livers of wild-type mice fed MD resulted in 
decreased level of collagen accumulation in their livers as compared to TLR-4+ kupffer cells-containing wild-type mice 
fed MD as shown by the (A) representative images of picrosirius red stained liver sections and expression of (B-C) 
Col-1a and α-SMA. On the other hand, reconstitution of wild-type kupffer cells in the livers of TLR-4 KO mice fed MD 
resulted in increased level of collagen accumulation in their livers as compared to TLR-4 KO kupffer cells-containing 
TLR-4 KO mice fed MD as shown by the (A) representative images of picrosirius red stained liver sections and 
expression of (B-C) Col-1a and α-SMA. CD and MD denote control diet and milk-based high fat diet, respectively. 
*P<0.05, ***P<0.001 (Man-Whitney test); data are expressed as mean±SEM; n=6-8. 
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Reconstituted kupffer cells were derived from the transplanted bone marrow 
It is an important question whether the kupffer cells can actually be reconstituted 
from the transplanted bone marrow.  To address this question, bone marrow cells isolated 
from CD45.1 mice were transplanted into lethally-irradiated and chlodronate-treated (to 
deplete existing kupffer cells) congenic CD45.2 mice.  Flow cytometric analyses of non-
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+
. That finding was in line with the 
















non-parenchymal cells isolated from the livers of recipient 
mice were CD45.2
+
.  These data demonstrate that bone marrow transplantation in 
lethally-irradiated and chlodronate-treated recipient mice results in the reconstitution of 















Figure 6.13. Reconstituted kupffer cells in the livers of bone marrow recipient mice are derived from the 
transplanted cells. Representative plots of flow cytometric analyses are showing that most of the live, non-parenchymal 
and Ly6G/SiglecFlowLy6ClowF-4/80+ cells in the livers of (A) donor, (B) recipient and (C) chimeric mice were CD45.1+, 







In chapter 5, the generalized involvement of gut microbiota in mediating NASH has 
been demonstrated.  Therefore, the next question to address is about the mechanism of 
how gut microbiota contributes to the modulation of chronic inflammation on the grounds 
of a fatty liver.  One important mechanism to associate gut microbiota with the 
pathogenesis of diseases is the production of microbe-associated molecular patterns to 
induce pro-inflammatory pathways through the interaction with pattern recognition 
receptors mostly expressed by the innate cells [223].  
Gut microbiota produces numerous types of microbe-associated molecular 
patterns in the intestine that can enter the systemic circulation and induce inflammatory 
responses through the interaction with their corresponding pattern recognition receptors 
[224, 225].  Therefore, it is not possible to distinguish the pro-inflammatory capability of 
individual microbe-associated molecular patterns when they are present together in the 
system.  In this study, we treated mice with broad spectrum antibiotics to diminish their 
gut microbiota and then injected them with LPS, which allowed us to study the effect 
solely mediated by this pro-inflammatory molecule without being affected by the 
responses mediated by others.  
TAK-242 is a small compound that selectively inhibits TLR-4 signaling through the 
interference with interactions between TLR-4 and its adaptor molecules [226]. 
Therapeutic effect of TAK-242 was shown in mouse models of sepsis and endotoxin-
shock [227, 228].  It was also trialed for the treatment of severe sepsis in human [229].  
To demonstrate the role of TLR-4 in the modulation of low grade LPS-mediated chronic 
inflammation in the fatty liver, broad spectrum antibiotics/LPS-treated mice fed MD were 
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injected with TAK-242 which blunted the inflammation induced by LPS.  The outcome 
from this experiment in mice promises TAK-242 as a potential therapeutic option for 
NASH in human.  Therefore, it could be used for clinical trial as a NASH drug in future. 
Noticeably, administration of TAK-242 in mice fed MD not only blunted the increase 
in levels of pro-inflammatory indicators of NASH in LPS-injected mice fed MD, but also 
reduced their levels lower than non LPS-injected control mice fed MD (Fig. 6.3-6.4).  It 
indicates a possibility that TAK-242 may interfere not only the LPS-TLR-4 pathway, but 
also other pro-inflammatory pathways in NASH.  Therefore, it could be a new topic of 
study to investigate the role of TAK-242 in the inhibition of different pro-inflammatory 
signaling in NASH. 
Besides kupffer cells, other types of cells in the liver e.g. hepatocytes, sinusoidal 
endothelial cells, stellate cells, and hepatic dendritic cells, are also known to express TLR-
4 [230, 231].  Therefore, the sole contribution of TLR-4-expressing kupffer cells in 
mediating NASH had remained unclear.  To address this question, kupffer cells in wild-
type mice were reconstituted by TLR-4 KO kupffer cells and kupffer cells in TLR-4 KO 
mice were reconstituted by wild-type kupffer cells through bone marrow transplantation.  
After induction of NASH, wild-type mice containing TLR-4 KO kupffer cells showed a 
reduced level of NASH as compared to the wild-type mice containing wild-type kupffer 
cells.  On the other hand, TLR-4 KO mice containing wild-type kupffer cells displayed an 
elevated level of NASH as compared to the TLR-4 KO mice containing TLR-4 KO kupffer 
cells.  Thus, our experiment clarified the essential role of TLR-4-expressing kupffer cells 
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Peroxisomes are one of the major sites for the generation and decomposition of 
reactive oxygen species (ROS), in particular hydrogen peroxide (H2O2).  Catalase is the 
H2O2-decomposing enzyme exclusively localized in peroxisomes. Catalase detoxifies 
H2O2 produced not only in peroxisomes but also in mitochondria through peroxisome-
mitochondria communication. Therefore, a compromised peroxisomal structure and 
function can lead to the accumulation of H2O2 that can exacerbate oxidative stress and 
inflammation. Sublethal dose of endotoxin in rat was reported to induce structural and 
functional alterations in liver peroxisomes which led us to investigate the role of TLR-4 
pathway in mediating any alteration in peroxisomal structure and anti-oxidative function 
in the steatotic livers of mice. Fluorescent Immunohistochemistry of peroxisomal 
membrane protein 70 (PMP70) and catalase in the liver sections of mice fed MD displayed 
a reduced level of immunofluorescence intensity, when compared to the mice fed control 
diet, indicating an altered peroxisomal structure and anti-oxidative function respectively.  
Fluorescence intensity of immuno-stained PMP70 and catalase significantly increased in 
the livers of TLR-4 KO mice fed MD, when compared to the wild-type mice fed MD, 
indicating that alteration of peroxisomal structure and anti-oxidative function in NASH is 
dependent on TLR-4 pathway.  Catalase activity assay using tissue homogenates from 
mice fed MD demonstrated a reduced level of catalase activity, as compared to the mice 
fed CD, which increased in TLR-4 KO mice fed MD.  These data indicated that TLR-4 
pathway mediates an alteration in peroxisomal structure and anti-oxidative function in 
NASH. Thus, our study provides a new insight into the pathophysiological mechanism of 




Peroxisomes are essential subcellular organelles which are ubiquitous in 
eukaryotic cells [232].  They have indispensable role in the synthesis of bile acids, myelin 
lipid plasmalogens, and docosahexaenoic acids and catabolism of long-chain fatty acids, 
very-long-chain fatty acids, and branched-chain fatty acids through a set of α and β-
oxidation reactions [232-234].   Apart from lipid catabolism, peroxisomes are also involved 
in degradation of polyamines, glyoxylate, certain amino acids, arachidonic acids, and 
several xenobiotics [234].  In addition, peroxisomes are also involved in generation and 
scavenging of reactive oxygen species (ROS) produced inside and outside this organelle 
[235].  Thus, peroxisomes play an important role in cell metabolism and metabolic 
homeostasis through communication with other organelles especially mitochondria [236]. 
Critical metabolic role of peroxisome is closely associated with the exertion of control over 
inflammatory responses.  Peroxisomes exert control over inflammation in three different 
ways.  First, degradation of pro-inflammatory arachidonic acids; second, synthesis of anti-
inflammatory docosahexaenoic acids; and third, scavenging of ROS.  
One important catabolic function of peroxisome is the degradation of arachidonic 
acid derivatives known as eicosanoids.  Commonly known eicosanoids are 
prostaglandins, thromboxanes, leukotrienes, and prostacyclins which have tremendous 
role in the elicitation of broad ranging inflammatory responses.  Most important pro-
inflammatory activities mediated by these molecules are vasodilation/vasoconstriction, 
leukocyte migration and platelet aggregation [237, 238]. 
Peroxisomes contain enzymes which contribute to the synthesis of 
docosahexaenoic acids.  Docosahexaenoic acids are peroxisomally produced omega-3 
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fatty acids used as precursors for resolvins, maresins and protectins.  These molecules 
possess potent anti-inflammatory and immunoregulatory functions [239-241].  
Peroxisomes play a dual role in generation and detoxification of ROS particularly 
hydrogen peroxide (H2O2).  Peroxisomes contain different oxidases that generate H2O2 
as a byproduct of their oxidation reactions.  These oxidases are co-localized with catalase 
which is exclusively found in peroxisomes.  Catalase decomposes H2O2 into H2O and 
molecular oxygen [242].  Catalase scavenges H2O2 generated not only in peroxisomes 
but also in extra-peroxisomal sites like mitochondria.  Peroxisomes and mitochondria can 
exchange their metabolites including H2O2 through intra-organellar diffusion, vesicular 
traffic or direct physical contact [236].  Therefore, depending on the abundance of 
peroxisomes within the cells and their catalase content, they can efficiently detoxify 
cellular H2O2 generated within the cells during the metabolic reactions [232, 233, 243]. 
Impaired detoxification of H2O2 by peroxisomes due to their structural and functional 
alterations in an inflamed milieu can result in an increased level of oxidative stress and 
thereby exacerbate the inflammation [235]. 
Liver is the key metabolic organ which governs the energy balance of the body 
[244].  Peroxisomes are most abundant in hepatocytes where they constitute round 1-2% 
of the total cell volume [245].  Thus, peroxisomes play the major role in the neutralization 
of bulk amount of H2O2 continuously produced in this metabolically active organ.  Hepatic 
steatosis results in enhanced production of H2O2 making the organ more dependent on 
peroxisomes for safe disposal of H2O2 [246].  Therefore, there is a concern about any 
impairment in peroxisomal function that can potentially exacerbate the oxidative stress in 
the steatotic liver and facilitate the progression of the disease to NASH.   
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Knowledge about an impaired peroxisomal function in NASH first came from the 
observation that homozygous mutation of the peroxisome proliferator-activated receptor-
α gene (PPAR-α), the key regulator of genes involved in peroxisomal proliferation, 
accumulate fat in the liver of mice under a starved condition [247].   Subsequent study 
showed that acyl-coenzyme A oxidase null mice, the rate limiting enzyme for peroxisomal 
β-oxidation, leads to the development of NASH, further indicating the role of impaired 
peroxisomal function in mediating NASH [248].  Therefore, we anticipated that there 
occurs an impairment in peroxisomal structure and antioxidative function in dietary fat 
mediated NASH.  It was reported that intraperitoneal injection of sublethal dose of LPS in 
rat alters the structure, number, and function of peroxisomes [249, 250].  Elevated 
expression of TLR-4 in the steatotic liver has been associated with the increased 
sensitivity to gut-derived LPS resulting in chronic inflammation [251, 252].  Therefore, in 
this current study, we examined the effect of TLR-4 pathway on peroxisomal structure 











Peroxisomal structure is altered in the livers of mice fed MD in a TLR-4 dependent 
manner 
Fluorescence immunohistochemistry of PMP70, a major component of 
peroxisomal membrane [253], in the liver sections of mice fed MD demonstrated a 
decreased fluorescence intensity as compared to the mice fed CD.  In the same time, 
immunofluorescence-stained liver sections of TLR-4 KO mice fed MD displayed an 
increased level of fluorescence intensity than WT mice fed MD (Fig. 7.1).  This data 
indicated that peroxisomal structure is altered in mice fed MD in a TLR-4-dependent 
manner. 
Catalase level and activity are decreased in the livers of mice fed MD in a TLR-4 
dependent manner 
An alteration in peroxisomal structure led us to investigate the plausible change in 
peroxisomal antioxidative function.  Fluorescence immunohistochemistry of catalase, a 
major antioxidative enzyme exclusively found in peroxisomes, in the liver sections of mice 
fed MD demonstrated a decreased fluorescence intensity as compared to the mice fed 
CD.  In the same time, immunofluorescence-stained liver sections of TLR-4 KO mice fed 
MD displayed an increased level of fluorescence intensity than WT mice fed MD (Fig. 
7.2).  This data indicated that catalase level is altered in mice fed MD in a TLR-4-
dependent manner. 
Western blot analysis demonstrated a decreased level of catalase in the livers of 
wild-type mice fed MD as compared to the wild-type mice fed CD. In the same time, 
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Catalase level was increased in TLR-4 KO mice fed MD (Fig. 7.3A-B).  This data indicated 
that the level of catalase in mice fed MD is decreased in a TLR-4 dependent manner 
which was consistent with the observation in fluorescence immunohistochemistry of 
catalase.  Of note, catalase level was also increased in TLR-4 KO mice fed CD compared 
to the WT mice fed CD.  This indicated the catalase level is very sensitive to the basal 
activity of TLR-4 pathway. 
Catalase activity assay was performed using liver tissue homogenates.  Catalase 
activity was decreased in wild-type mice fed MD as compared to the wild-type mice fed 
CD. Catalase activity significantly increased in TLR-4 KO mice fed MD as compared to 
the wild-type mice fed MD indicating the role of TLR-4 pathway-mediated chronic 
inflammation on catalase activity in NASH (Fig. 7.3C). Catalase activity data was 
consistent with the level of catalase displayed by fluorescence immunohistochemistry and 




















Figure 7.1. Fluorescence immunohistochemistry of peroxisomal membrane protein 70 in liver sections 
displayed a reduced level of fluorescence intensity in mice fed milk-based high fat diet in a TLR-4 
dependent manner. Immunofluorescence staining of peroxisomal membrane protein 70 in liver sections 
displayed a reduced level of fluorescence intensity in WT mice fed MD as compared to the WT mice fed CD. 
Fluorescence intensity increased in TLR-4 KO mice fed MD as compared to the WT mice fed MD. CD and MD 









Figure 7.2. Fluorescence immunohistochemistry of catalase in liver sections displayed a reduced level 
of fluorescence intensity in mice fed milk-based high fat diet in a TLR-4 dependent manner. 
Immunofluorescence staining of catalase in liver sections displayed a reduced level of fluorescence intensity in 
WT mice fed MD as compared to the WT mice fed CD. Fluorescence intensity increased in TLR-4 KO mice fed 










Figure 7.3. Catalase level and activity are decreased in the livers of mice fed milk-based high fat diet which 
is dependent on TLR-4. Catalase level and activity were decreased in the livers of mice fed MD as compared to the 
mice fed CD in TLR-4 dependent manner as shown by (A) Western blot analysis (B) Image J analysis of the Western 
blot image and (C) catalase activity assay. CD and MD denote control diet and milk-based high fat diet, respectively. 






Reactive oxygen species (ROS) are endogenously produced as byproducts of 
cellular metabolic processes in mitochondria and peroxisomes [254, 255]. Cellular 
homeostasis mediated by anti-oxidant defense system prevents the accumulation of ROS 
within the cells. When the level of ROS overwhelms the anti-oxidant defense system, 
whether through an excessive production of ROS or a reduction of anti-oxidant defense 
capacity, oxidative stress occurs [256]. A sustained oxidative stress can lead to chronic 
inflammation which can potentially serve as a cause of different advanced stage diseases 
[257, 258].  
Peroxisomes are single membrane-bounded ubiquitous organelles in eukaryotic 
cells [255].  Several metabolic processes, including catalase-mediated detoxification of 
H2O2, exclusively occurr in peroxisomes [259].  The number, morphology, and activity of 
peroxisomes can remarkably vary depending on the tissue, organ, and nutritional and 
metabolic status [236].  Peroxisomes produce different ROS from different metabolic 
pathways that are neutralized by enzymatic and non-enzymatic anti-oxidant defense 
systems.  Catalase is a unique member of peroxisomal anti-oxidant defense system 
which neutralizes H2O2 in a catalytic (2 H2O2 → 2 H2O + O2) or peroxidatic 
(H2O2 + AH2 → A + 2 H2O) manner [259].  Although catalase is localized exclusively 
within peroxisomes, they can decompose H2O2 produced not only in peroxisomes but also 
in extra-peroxisomal sites such as mitochondria through inter-organellar exchange of 
metabolites [236].  Thus, catalase-mediated detoxification of H2O2 in peroxisomes plays 
an indispensable role in preventing the cell from reaching the stage of oxidative stress. 
Besides catalase, peroxisomes are also required for the biosynthesis of plasmalogens. 
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Plasmalogens are ether-phospholipids known to have anti-oxidative function, but it is still 
unclear how much role they play in providing anti-oxidative defense [260].  
Oxidative stress is the key mediator of NASH, which is caused by the increased 
availability of free fatty acids in the steatotic livers [261, 262].  Therefore, NASH-affected 
livers are in increased demand of anti-oxidative mediators.  Impaired detoxification of 
H2O2 in NASH-affected livers due to any alteration in peroxisomal structure and function 
may exacerbate the severity of the disease.  In this study, we have shown that the 
catalase level and activity decrease in the livers of mice model of NASH which are 
reversed in TLR-4 KO mice indicating the role of TLR-4 pathway in the modulation of anti-
oxidative function of catalase.  It may be due to the adverse effect of TLR-4 pathway-
mediated low grade chronic inflammation on the structure and/or function of peroxisomes 
in the fatty liver.  Not only in TLR-4 KO mice fed MD, we have also observed an increase 
in catalase level and activity in the livers of TLR-4 KO mice fed CD as compared to the 
wild-type mice fed CD.  It might be due to the sensitivity of peroxisomal structure and 
function to the basal activation of TLR-4.  
The findings presented in this study are in line with previous reports demonstrating 
the role of endotoxin-induced inflammation in alteration of peroxisomal structure-function 
in the liver [249, 250]. Endotoxin-induced inflammation causes change in lipid 
composition of peroxisomes in the liver [250].  Because the concentration of circulating 
endotoxin is increased in NASH, it is important to know how the lipid composition of 
peroxisomes are affected in NASH.  Besides endotoxin-induced inflammation, increased 
concentration of free fatty acids is also an important contributor to organelle malfunction.  
Increased concentration of free fatty acids alters the lipid composition in mitochondria and 
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endoplasmic reticulum, resulting in their impaired function [263, 264]. Because fat 
accumulation in the liver results in an increased concentration of free fatty acids, it 
demands a comprehensive study to determine the changes in structural composition of 
peroxisomes to have a clearer picture on their impaired anti-oxidative function in NASH.  
TLR-4 pathway-mediated alteration of peroxisomal structure/function in NASH may not 
only reduce their anti-oxidative activity but also impact the peroxisome-mediated 
synthesis of anti-inflammatory and degradation of pro-inflammatory molecules. 
Therefore, it requires a further investigation to study the effect of TLR-4 pathway on the 
peroxisomal metabolism of different pro and anti-inflammatory molecules potentially 










































Because chronic inflammation is the principal reason for the progression of a 
benign fatty liver into an end stage disease, the ultimate goal of all NASH research is to 
stop the inflammation.  To stop the inflammation in the fatty liver, it is urgent to reduce the 
availability of causative agents of inflammation, or therapeutically interfere with their 
signaling pathways.  In this project, gut microbiota has been studied as a potential source 
of pro-inflammatory agents of NASH.  We have comprehensively investigated the role of 
the gut microbiota-derived LPS-TLR-4 pathway as a potential mediator of NASH with 
therapeutic relevance, using an appropriate experimental model. 
Study of NASH in mice fed high fat diet represents a clinically relevant model 
When compared to other genetic and diet-based models of NASH, high fat diets 
are clinically more relevant for some genuine reasons.  First, high fat diets do not contain 
any ingredient that is unusual in the regular human diet.  In fact, high fat diets are prepared 
from sources that are commonly consumed by humans, e.g., vegetable oil, coconut oil, 
milk fat, beef tallow, lard  and other sources [265].  Second, high fat diets mimic western 
diets  in having high fat content [266].  Third, high fat diets induce the development of 
NASH spontaneously without requiring any additional dietary intervention [150].  When 
compared to other dietary models, high fat diets require a longer period of feeding to 
induce NASH.  For instance, a methionine and choline deficient diet induces NASH at 
day 10 of feeding, whereas a high fat diet requires 8-12 weeks [133, 142, 150, 267].  This 
requirement of long-term feeding is  consistent with NASH patients requiring a long period 
of pathogenesis [150].  Finally, high fat diets result in the development of obesity and 
NASH simultaneously, which is a common scenario in the case of NASH patients [150].  
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Therefore, high fat diets offer an opportunity to study NASH within the context of metabolic 
syndrome, which is known to manifest as NAFLD in the liver. 
Both unsaturated and saturated fats are present in regular human diets [157].  The 
role of saturated fats in inducing steatosis and chronic inflammation in the liver has been 
demonstrated in numerous reports [160-163].  In line with those findings, we designed a 
comparisonal study between a milk-based saturated high fat diet and a lard-based 
saturated diet, thus demonstrating the higher efficiency of a milk-based saturated high fat 
diet over a lard-based unsaturated high fat diet in inducing NASH.  We also performed an 
experiment where mice were fed at  three different time points (8, 16 or 32 weeks) 
resulting in a significantly higher level of NASH at weeks 16 and 32, as compared  to 
week 8.  Based on these results, we fed mice with a milk-based saturated high fat diet for 
16 weeks to ensure a maximum level of steatosis and inflammation in the remaining 
experiments of the study. 
To keep our animal study consistent with human patients, it was important to 
evaluate the level of disease with methods similarly used for diagnostic purposes in 
humans.  We used both noninvasive and invasive methods to detect and measure the 
level of NASH in mice.  In the case of human patients, noninvasive methods are of first 
preference.  Imaging techniques, e.g., ultrasonography, computerized tomography, and 
magnetic resonance imaging are widely used noninvasive methods to identify fat 
deposition in the liver.  One major limitation of those imaging methods is that they cannot 
distinguish steatosis from NASH [268-271].  Therefore, imaging methods were of no use 
in our NASH study on animal models.  Assays employed for determining ALT and AST 
activities in serum are also commonly used noninvasive methods of NASH diagnosis.  
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Elevated levels of ALT and AST activity in serum indicates hepatocyte damage 
subsequent to hepatic inflammation.  Those levels can rise up to five fold in NASH 
patients compared to their upper limits in healthy individuals.  Although ALT and AST 
activity in serum cannot give an accurate indication about the degree or severity of liver 
disease, those markers were used as an important indicator of NASH in our study [268, 
272, 273].  Apart from those noninvasive methods, liver biopsy is the most reliable 
invasive technique to diagnose NASH.  Biopsy samples are used for histology that can 
diagnose as well as evaluate the level of disease.  Biopsy sections are evaluated based 
on steatosis, inflammation, hepatocyte ballooning, necrosis, and fibrosis. Yet liver 
histology is a controversial tool to diagnose NASH in humans due to the risks of biopsy 
and the validity of a tiny biopsy for representing NASH in the entire liver [272, 274].  Due 
to the availability of tissue post euthanization, liver histology is an unquestionably useful 
method for disease evaluation in animal models of NASH.  Thus, because of the 
application of different, clinically used noninvasive and invasive indicators of NASH, our 
study outcome has strong clinical relevance.  
Gut microbiota spans gut-liver axis in causing NASH 
In this project, we also studied the role of gut microbiota in mediating NASH.  We 
found a reduced level of dietary fat-mediated chronic inflammation in the livers of mice 
that were germ free or treated with broad spectrum antibiotics, as compared to control 
mice.  Mechanisms explaining the communication between the gut microbiota and NASH 
are still widely investigated.  A large body of evidence from both population and animal 
studies clearly indicates that changes in the composition of gut microbiota are closely 
associated with NASH.  One widely studied mechanism of gut microbiota in inducing 
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NASH is altered production of metabolites.  For instance, changes in gut microbiota of 
NASH patients result in higher abundance of Escherichia and increase the level of 
endogenous alcohol in the circulation, leading to the increased production of ROS in the 
liver [275, 276].  Another important metabolic role of gut microbiota is the production of 
short chain fatty acids, which provide nutrients and energy essential for maintaining gut 
health and integrity.  An altered production of short chain fatty acids results in defective 
gut permeability, leading to an increase of pro-inflammatory microbial elements in the 
portal circulation [277].  Gut microbiota also has an important role in the regulation of 
intestinal lipid absorption mediated by the deconjugation of bile acids in intestine.  
Deconjugation of bile acids is mediated by the removal of polar groups of 
glycine and taurine catalyzed by gut microbial enzymes.  Impaired deconjugation of bile 
acids can lead to increased emulsification and absorption of dietary fat, resulting in 
hepatic steatosis [277, 278].  It is still not clear whether the abundance of microbes 
expressing the enzymes associated with bile acid deconjugation is altered in NASH. 
Apart from their metabolic functions, the supply of pro-inflammatory microbes-
associated molecular patterns into the liver is also a potential mechanism of gut 
microbiota in mediating NASH.  Prominent microbes-associated molecular patterns 
involved in NASH include endotoxin, peptidoglycan, flagellin, and microbial nucleic acids 
[279].  In this comprehensive study, we demonstrated the role of gut-derived LPS in 
mediating NASH through the TLR-4 receptor. 
Gut microbial community gets changed in NASH 
The role of specific microbes has been reported to induce different inflammatory 
diseases in mice fed a high fat diet.  A milk-based saturated fat diet can induce colitis in 
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IL10-/- mice through the expansion of Bilophila wadsworthia [159].  The Enterobacter 
cloacae B29 strain isolated from the gut of an obese human has been shown to induce 
obesity and insulin resistance in germ free C57BL/6J mice fed a high fat diet, whereas  
germ free control mice on a high-fat diet were protected from disease phenotypes [280].  
Our current project revealed an overall change in the structure of gut microbial community 
in mice fed MD, but we could not identify a specific microbe associated with NASH.  
Therefore, it is important to undertake a future investigation to identify microbes whose 
presence could be directly related to the pathogenesis of NASH. 
Feeding mice with a high fat diet has been reported to result in increased 
concentration of circulating endotoxin [122, 123].  Consistent with those reports, we have 
shown a trend of higher concentration of endotoxin in the portal serum of mice fed MD, 
as compared to the mice fed CD.  Those data led us to investigate whether the 
composition of gut microbiota is changes, resulting in an increased abundance of Gram 
negative bacteria in mice fed MD.  However, our 16s rRNA analysis displayed a decrease 
in the relative abundance of Bacteroidetes, the major Gram negative phylum in gut 
microbiota in mice [281].  Yet the relative abundance of Proteobacteria, another important 
Gram negative phylum in the gut microbiota of mice, was significantly increased [282].  
Further investigation is required to determine if the entire phylum of Proteobacteria or any 
specific microbe within the phylum, plays a key role in mediating chronic endotoxemia in 
mice fed MD. 
Altered gut permeability facilitates the elevation of circulating endotoxin level 
The elevated concentration of gut microbiota-derived pro-inflammatory 
components in the circulation of NASH patients, especially endotoxin, is mediated by 
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increased gut permeability [283, 284].  However, a comprehensive assessment in an 
animal model is yet to be performed in order to explain the relationship between gut 
permeability and NASH.  In the case of obesity, an increased level of TNF-α in the serum 
has been associated with inflammation in the intestine leading to gut leakage [285].  In 
our study, a higher level of expression of TNF-α was observed in the livers of NASH-
affected mice.  Therefore, it is possible that an increased production of TNF-α in the 
altered cytokine milieu of NASH eventually leads to the inflammation in intestine.  
Additionally, changes in gut microbiota in NASH may also alter intestinal permeability 
through the pathways driven by bacterial metabolites.  Zhu and colleagues reported that 
expression of alcohol-metabolizing enzymes are up-regulated in NASH livers [276].   In a 
follow-up study, they reported that the abundance of alcohol-producing Escherichia is 
increased in the gut of NASH patients as compared to non-obese and obese non-NASH 
controls, leading to an elevated concentration of alcohol in the blood serum of NASH 
patients [275].  Gut microbiota-produced alcohol is known to have a potential role in 
increasing gut permeability [286] and the generation of reactive oxygen species in the 
liver [287].  Thus, gut permeability and NASH participate in a positive feedback loop in 
causing the disease. In our animal study, Clostridium was the only alcohol-producing 
genus whose abundance was increased in the gut microbiota of NASH.  Further 
investigation is required to determine the extent to which Clostridium contributes to the 
mediation of gut permeability. 
LPS-TLR-4 pathway plays an essential role in mediating NASH 
Using a unique approach, we studied the role of LPS in causing NASH through the 
injection of LPS in mice treated with broad spectrum antibiotics.  The purpose of LPS 
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injection in broad spectrum antibiotics-treated mice was to ensure the presence of LPS 
in the system as the sole pro-inflammatory agent derived from microbes.  Therefore, the 
TLR-4-mediated inflammation in the fatty liver was attributed only to LPS, not to any other 
microbial agents.  Apart from microbes-derived LPS, there are  many endogenous host-
derived ligands of TLR-4 with varying activation potential, e.g., low-molecular weight 
hyaluronic acid, heparin sulfate, saturated fatty acid, fibrinogen, fibronectin, heat shock 
proteins 60 and 70, high mobility group box-1, and degraded matrix [288].  It is still not 
clear what level of TLR-4 activation is contributed by these endogenous ligands.   
The level of TLR-4 pathway activation can vary depending on the types of LPS.  
Acylation of lipid A, the actual site of LPS recognized by TLR-4, can vary in terms of 
number, length, and saturation level of fatty acyl chains [289].  While human TLR-4 can 
sense only hexaacyl lipid A, murine TLR-4 can sense pentaacyl or tetraacyl lipid A [290].  
Furthermore, lipid A attached with saturated fatty acyl chains with lengths of 12 or 14 (or 
occasionally 16)  are better agonists of TLR-4 [291].  In the complex ecology of gut 
microbiota, LPS molecules with different types of lipid A are produced.  Therefore, it is 
important to investigate whether the altered gut microbiota in the mice fed a high fat diet 
produce higher levels of those types of LPS, which are stronger agonists of TLR-4. 
TLR-4 pathway is a promising target for therapeutic intervention against NASH and 
ischemia/reperfusion injury in liver transplantation 
High fat diet-mediated hepatic steatosis in TLR-4 KO mice displayed a reduced 
level of inflammation as compared to the wild-type mice; even the chronic administration 
of low dose LPS could not increase the level of inflammation in the fatty liver of TLR-4 KO 
mice.  Those data demonstrated the prospect of TLR-4 pathway as a therapeutic target 
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for the treatment of NASH.  In our study, we administered TAK-242, an inhibitor of TLR-
4, in LPS-injected mice fed a high fat diet, resulting in a significant decrease in the levels 
of NASH-indicative markers.  TAK-242, a novel synthetic molecule with the chemical 
name resatorvid, suppresses TLR-4 signaling by selectively binding to the TIR domain 
via Cys747 [292-294].  Although several studies have reported the protective role of TAK-
242 against acute inflammation in different disease conditions, it is still not clear how 
efficient TAK-242 may be in inhibiting chronic inflammation.  TAK-242 has demonstrated 
protective effects against Escherichia coli-induced sepsis and acute endotoxemic shock 
in mice [227, 228].  Most importantly, TAK-242 has been tested on a trial   to treat severe 
sepsis in human patients [229].  The findings from studies on TLR-4-miediated acute 
inflammation indicate a plausible role for TAK-242 in inhibiting TLR-4-induced chronic 
inflammation.  Thus, in our study, data on the protective role of TAK-242 against NASH 
in mice offer   therapeutic promise for the treatment of NASH in human patients. 
The TLR-4 pathway has been correlated not only with chronic inflammation in 
NASH, but also with warm ischemia/reperfusion injury in liver transplantation [295].  
Circulating endotoxin is a critical factor in causing injury in the liver following 
ischemia/reperfusion.  Steatotic livers are more sensitive to endotoxin in developing 
ischemia/reperfusion injury compared to their lean counterparts [296].  Our lab has 
reported that the neutralization of endotoxins through  treatment with anti-endotoxin 
monoclonal antibody  dramatically improved survival rate and liver function after 
ischemia/reperfusion injury in mice with hepatic steatosis [297].  We also reported that 
deficiency of TLR4 is protective against ischemia/reperfusion injury in the mouse steatotic 
liver [296].  Therefore, we anticipate that inhibition of the TLR-4 pathway through the 
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treatment with TAK-242 would be protective against ischemia/reperfusion injury in 
steatotic liver. 
Therapeutic interference of LPS-TLR-4 pathway may improve hepatic regeneration 
following partial hepatectomy in steatotic liver 
We have studied the impact of dietary fat mediated NASH in the impairment of 
hepatic regeneration following partial hepatectomy.  No study has yet investigated the 
role of gut microbiota or the role of the LPS-TLR-4 pathway in modulating the impairment 
of hepatic regeneration following partial hepatectomy in the steatotic liver.  Such a study 
could result in a novel drug with therapeutic potential for the treatment of impaired hepatic 
regeneration in NASH.  In this project, we have shown that the TLR-4 inhibitor, TAK-242, 
can suppress chronic inflammation in the fatty liver.  Therefore, treatment of mice with 
TAK-242 before surgical resection is anticipated to inhibit the pro-inflammatory insult on 
the regenerating lobes of the liver and thereby improve impaired regeneration.  It has also 
been demonstrated in this project that diminishing of gut microbiota through treatment 
with broad spectrum antibiotics results in a reduced concentration of serum endotoxin 
and a decreased level of NASH.  Therefore, treatment of mice with broad spectrum 
antibiotics before partial hepatectomy surgery is anticipated to result in an improved 
regeneration outcome. 
 A published study from our lab demonstrated that pre-treatment of obese mice 
(ob/ob) with anti-endotoxin monoclonal antibodies could protect them from subsequent 
hepatic ischemia/reperfusion injury, indicating the role of circulating endotoxin in 
mediating the inflammatory cascade in the steatotic liver [298].  Therefore, pretreatment 
of mice with anti-endotoxin monoclonal antibodies prior to partial hepatectomy could 
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potentially reduce the level of inflammation by sequestering the endotoxins from binding 
to Kupffer cells, thereby ameliorating hepatic regeneration.  
Why peroxisomes are important in controlling oxidative stress 
In mammals, peroxisomes play an indispensable role in numerous metabolic 
pathways including fatty acid α- and β-oxidation.  During those metabolic processes, 
peroxisomes produce a bulk amount of ROS as byproducts of different biochemical 
reactions that are efficiently neutralized, using a set of enzymatic and non-enzymatic 
defense mechanisms [236].  Except for catalase, most of those anti-oxidant defense 
mechanisms are common in other metabolically active organelles, especially 
mitochondria [242].  Catalase is the H2O2-detoxifying enzyme in the cell [299].  Catalase 
is exclusively localized in peroxisomes, but H2O2 is generated in both peroxisomes and 
mitochondria.  In fact, only 35% of H2O2 within the cell is generated by peroxisomes in the 
rat liver [242].  H2O2 generated in mitochondria is also decomposed by peroxisomal 
catalase, which is mediated by peroxisome-mitochondrial communication [236].  
Therefore, peroxisomes play a major role in controlling oxidative stress by preventing the 
accumulation of ROS. 
Peroxisomal anti-oxidative function is impaired in NASH 
Regular peroxisomal function in the healthy liver serves two important beneficial 
roles simultaneously.  One is the degradation of very long chain and branched-chain fatty 
acids, thus preventing them from being accumulated in the liver to induce hepatic 
steatosis; the other is the neutralization of ROS, preventing them from causing oxidative 
stress [246, 300].  Up-regulation of peroxisomal biogenesis leads to a resistance to 
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dietary fat-mediated hepatic steatosis in mice [301].  On the other hand, peroxisome-
deficient mice develop an increased level of hepatic steatosis [302].  Recently,  Park and 
colleagues  have reported that expression of peroxisomal proliferator-activated receptor-
α (PPAR-α), the master regulator of peroxisomal fatty acid oxidation and proliferation, is 
reduced in methionine- and choline-deficient diet-induced NASH in mice [303].  They 
have also shown that statin-mediated inhibition of hepatic steatosis and NASH recovers 
the expression level of PPAR-α.  Those data indicate an impaired peroxisomal function 
in NASH that is consistent with the reduced catalase level and activity demonstrated in 
the livers of mice fed MD in our study.  It is still not clear if the decreased level and activity 
of catalase in NASH is due to the reduced biogenesis or structural alteration of 
peroxisomes. 
Intervention of TLR-4 pathway can improve peroxisomal anti-oxidative function 
In this project, we have demonstrated that the catalase level and function increase 
in TLR-4 KO mice fed MD as compared to the wild-type mice fed MD, indicating an 
important role for the TLR-4 pathway in regulating peroxisomal function in NASH.  The 
impact of the TLR-4 pathway on peroxisomal function might be mediated in two different 
ways: a) alteration of peroxisomal structure as a direct influence of pro-inflammatory 
milieu, and b) cross-talk between the TLR-4 pathway and the biogenesis of peroxisomes, 
leading to their reduced proliferation.   The impact of the TLR-4 pathway in the alteration 
of peroxisomal structure has been indicated in studies by Khan and colleagues [249, 250].  
They have shown that administration of a sub-lethal dose of endotoxin induces changes 
in peroxisomal structure and function in the rat liver. 
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 Possible crosstalk between the TLR-4 pathway and peroxisomal biogenesis has 
been indicated in a study by Necela and colleagues [304].  They have shown that 
activation of the TLR-4 pathway leads to the downregulation of peroxisomal proliferator-
activated receptor-γ (PPAR-γ) through an NF-κB-dependent mechanism in 
macrophages.  They have also shown that knockout of PPAR-γ results in an increased 
expression of pro-inflammatory genes, indicating a regulatory feedback loop between 
TLR-4 pathway and expression of PPAR-γ.  Because PPAR-α and PPAR-γ share 
similarity in their ligands and mechanism of inducing gene expression [305], the existence 
of similar type of regulatory feedback loop between TLR-4 and PPAR-α cannot be ruled 
out.  Because PPAR-α is the key transcription factor in  the PPAR family that regulates 
the expression of genes involved in peroxisomal β-oxidation and proliferation, it is 
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